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The hallmark of adaptive immunity is the production of specific antibodies. This process is 
initiated upon the ligation of the B cell antigen receptor (BCR) which activates multiple 
intracellular signaling cascades through the phosphorylation of the B cell ‘master regulator’: 
SLP65. Our lab found that in order to function, SLP65 interacts constitutively – in a 
stimulation independent manner, with molecules of the CIN85/CD2AP-family of adaptor 
proteins, harbouring multiple protein interaction domains.  
Mouse models with B-cell specific CIN85 deletion and patients with a germline deletion in 
CIN85 encoding gene have shown that CIN85 is mandatory for B cell activation and the 
subsequent B cell responses. The molecular basis of the mechanism driving this, however, 
needed further elucidation. The primary cells pose a limitation to the scope of genetic and 
mechanistic studies due to the scarce availability of the reserve. I addressed these aspects 
through the generation of CIN85-deficient B cells from the established B cell lines, followed 
by subsequent deletion of CD2AP.  
The cellular system thus created was used to conduct genetic and biochemical functional 
assays to assess how these proteins work. I observed that CIN85 significantly impacts the 
Ca2+ flux upon BCR-ligation. Moreover, CIN85 could additionally affect an upstream NF-
κB pathway signaling element called PKCβ. I also used the abovementioned 
CIN85/CD2AP-double deficient cells to investigate further binding partners of SLP65 
employing SILAC-based mass spectrometry to look for possible functional redundancies.    
In our collaboration with Prof. C. Griesinger’s group, we found that CIN85 and SLP65 
undergo phase-separation into supramolecular-clusters, representing the more recent and 
exciting intracellular compartments of membrane-free, mini-organelles, that orchestrate 
signaling in B cells. Due to their capacity to interact with multiple signaling elements, 
droplet signalosomes could be the modus operandi for CIN85/CD2AP-family of adaptor 
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Chapter 1: Introduction  
1.1 Basic concepts in Immunology, a brief overview of the Immune system and 
identifying the B lymphocytes   
The immune system is the host’s defence system, the loyal battalion bestowed with the 
ardent task of protecting the host against the pathogenic invaders or occasionally, the 
cellular-traitors within, like tumour cells. Ready to combat, are the soldiers that comprise of 
a vastly complex network of circulating molecules and cells that extend up to the higher 
ranks of specialised tissues and organs. In the strategic defence for the purpose of deterring, 
resisting, and repelling a strategic offensive, the immune system employs two components: 
the innate and the adaptive components, with much crosstalk between the two branches. The 
innate branch of the immune system provides the first line of defence. It consists of pre-
existing systems, for example, the anatomical barrier of the epithelial layer and the mucosa 
lining that provide physical obstruction to the pathogen invasion. It is a conserved, germline 
encoded-strategy to mount a set of  non-specific immune responses, to recognize a broad 
range of conserved pathogenic patterns. They act rapidly, bypass the need for previous 
exposure to elicit a full response and mediate pathogen clearance (Medzhitov & Janeway, 
2000).  
 
The adaptive immune system evolved to mount a more specific-immune response against 
the diverse pathogens and confers memory for subsequent similar encounters with that 
pathogen (Flajnik & Masanori, 2008; Parkin & Cohen, 2001). It may take several days or 
weeks to become fully activated and utilizes both cell-mediated and humoral responses, 
mediated by the T lymphocytes and the B lymphocytes respectively (Coico R. et al., 2003). 
These cells express receptors that recognize specific structures on pathogens called 
‘antigens’. On binding with the cognate antigen, the cells undergo proliferation, resulting in 
expansion of the antigen-specific clonal population. In the case of T lymphocytes, this results 
in either direct killing of intracellular pathogens by the cytotoxic T cells, or provision of 
support to B-lymphocytes mediated by the helper T cells (Zúñiga-Pflücker, 2004). In 
contrast, B lymphocytes present the host with humoral immunity by production of the  
 





soluble mediators called ‘antibodies’. Antibodies are produced by the terminally 
differentiated B cells called plasma cells. The important effector functions of the antibodies 
include direct pathogen masking/neutralization or opsonisation mediated subsequent 
activation of effector cells. The effector cell mediates phagocytosis or killing of antibody-
coated target cells – expressing tumor or pathogen derived antigens on their surface in a 
process called antibody dependent cellular toxicity (ADCC) (Cooper, 2015; Flajnik & 
Masanori, 2008). 
 
1.2 BCR signal transduction: A labyrinth of signaling cascades 
The generation of mature B cells continues throughout life in the adult bone marrow. This 
serves a critical purpose. During the lifetime of an individual, the capacity to recognize 
diverse antigenic structures requires diverse, high-affinity antigen recognizing assemblies 
rendered by the random re-arrangement of the immunoglobulin genes in a process called 
somatic recombination (as opposed to genetic recombination). This, in addition to the ability 
of a selected B cell to clonally proliferate in response to an infection, are the primary 
hallmarks of adaptive immunity (Yam-Puc et al., 2018).  
 
For combating the myriad pathogens in the environment by the production of antibodies, the 
B cells are equipped with a sample of the protective antibody produced by each clone as a 
component of the cell’s antigen receptor called the ‘B-cell antigen receptor’ (BCR). 
Depending on the developmental stage, the signals initiated by the BCRs play a decisive role 
in determining the ultimate fate of the B cells: activation, proliferation and differentiation 
into antibody secreting plasma cells or alternatively, anergy, apoptosis for autoreactive B 
cells (Niiro & Clark, 2002).  
 
A single BCR  is a complex of multiple proteins, the membrane bound immunoglobulin 
(mIg) responsible for recognition of the cognate antigen and the Igα (CD79α)/Igβ (CD79β) 
heterodimer as the signal transduction units for the subsequent relay of the signal to the 
intracellular  effector proteins (Reth M., 1992). As mentioned above, somatic recombination 
in the gene segments encoding the  antigen recognizing region of mIg, during B cell 
development in bone marrow, results in BCRs that can recognise their cognate antigens with  
 





significantly higher affinity (Honjo et al., 2002; Brack et al., 1978). 
 
The naïve B cells are characterized by the expression of either mIgM and/or mIgD class of 
BCRs on the surface of their cells (Havran et al., 1984). On antigen-encounter, in addition 
to exhibiting respective antibody secretions, these B cells undergo class-switching to a 
different Ig isotype in specialised regions in lymphoid organs called the germinal centres 
(GCs). This produces B cells expressing IgG, IgA or IgE class of BCRs and secreted 
antibodies (Honjo et al., 2002). Class-switching enables the B cells to mount a response 
directed towards a specific class of pathogens thus mediating varying effector functions. For 
instance, soluble IgG is associated with antiviral responses (Hangartner et al., 2006), IgE is 
known to elicit a response against parasites such as helminths (Fitzsimmons et al., 2014) and 
IgA present primarily in mucosal secretions inhibits pathogen invasion from the respiratory 
and gastrointestinal lumen (Woof & Kerr, 2004).  
 
For the general purpose of antigen-specific activation of the BCR, two models have been 
suggested. The dissociation activation model (DAM) proposes that BCRs in resting cells 
exist as signaling inactive oligomers and undergo dissociation into an activated state upon 
antigen ligation (Fiala et al., 2013; Reth M., 2001). Proponents of the more established 
model, the cross-linking model (CLM) propose that BCRs are dispersed on the surface of B 
cells as inert monomers and the antigen mediated BCR dimerization initiates signaling from 
the receptor. Regardless of the questions raised about the factual accuracy of either of the 
two models, the downstream signal transduction events are fairly similar.  
 
The antigen ligation to the BCR results in phosphorylation of the immunoreceptor tyrosine-
based activation motifs (ITAMs) in the cytosolic chains of Igα and Igβ. Src-family kinases, 
Lyn and the spleen tyrosine kinase (Syk) are responsible for the phosphorylation of the 
ITAM (Dal Porto et al., 2004). Additionally, this interaction further enhances the activity of 
Syk (Rowley et al., 1995). Syk then phosphorylates a non-ITAM tyrosine residue in the 
cytoplasmic tail of  Igα. This serves as a docking site for the SH2 domain of the central B 











Figure 1: Intracellular signaling cascades initiated on ligation of the B cell antigen receptor (BCR). 
Antigen mediated BCR activation results in activation of Src-family kinases such as Lyn and Syk, which in 
turn phosphorylate the ITAMs in Igα/Igβ heterodimer and a non-ITAM tyrosine in Igα. The translocation of 
Syk to the phosphorylated ITAMs assists the assembly of the trimolecular Ca2+ initiation complex. This 
complex consists of SLP65, Btk and PLCγ2. PLCγ2 hydrolyzes PIP2 to release IP3 and DAG second 
messengers. The release of IP3 commences the biphasic Ca2+ flux with the release of Ca2+ from the ER stores 
in the first phase, followed by the influx of Ca2+ across the plasma membrane in the second phase, all 
culminating in NFAT transcription factor activation. Membrane bound DAG and the cytosolic Ca2+ 
additionally facilitate the plasma membrane recruitment and activation of the enzyme PKCβ. Activated PKCβ 
phosphorylates and activates further downstream signaling elements, essentially the CBM complex eventually 
leading to the release and nuclear translocation of the NF-κB transcription factors. The ERK signaling pathway 
is activated along the Grb2-SOS axis. CD19 provides the necessary co-stimulatory signals. Recruitment of 
PI3K results in production of PIP3, leading to the activation of the PKB/Akt pathway. The diverse pathways 
converge in the nucleus with the activated transcription factors initiating specific gene transcription. Indirect 













SLP65 undergoes Syk mediated phosphorylation at multiple sites (Engels et al., 2001; 
Wienands et al., 1998; Zhang et al., 1998). Phosphorylated SLP65 recruits Bruton’s tyrosine 
kinase (Btk) and its substrate Phospholipase C-gamma-2 (PLCγ2) to assemble the Ca2+ 
initiation complex (Kurosaki & Tsukada, 2000). Important to note here is that the adaptor 
protein CIN85 has been reported to be a constitutive interactor of SLP65 resulting in a steady 
complex formation. This interaction is a prerequisite for the plasma membrane recruitment 
of SLP65 and its phosphorylation (Oellerich et al., 2011).  
 
PLCγ2 present in the Ca2+ initiation complex hydrolyzes the membrane bound phosphatidyl-
4,5-bisphosphate (PIP2) into membrane-bound diacylglycerol (DAG) and soluble inositol-
1,4,5-trisphosphate (IP3). IP3 binds the IP3 receptor (IP3R) on the ER membrane which 
initiates  the release of Ca2+into the cytosol along the concentration gradient, marking the 
first phase of the biphasic-Ca2+ flux. Reduction of Ca2+ in the ER is sensed by an ER 
membrane protein called the stromal interaction molecule 1 (STIM1). 
 
STIM1 can then induce Ca2+ influx across the plasma membrane via opening of Ca2+ release 
activating channels (CRAC) in the plasma membrane culminating the second phase of Ca2+ 
mobilization in B cells (Engelke et al., 2007). The surge in cytosolic Ca2+ concentrations 
presents an essential indicator for B cell activation and is commonly used as a valuable 
readout system for the flowcytometric experiments. Ca2+-bound Calmodulin then activates 
the phosphatase Calcineurin, which in turn dephosphorylates Nuclear factor of activated T 
cells (NFAT) transcription factor, also present in B cells.  NFAT then translocates into the 
nucleus and induces gene transcription (Bhattacharyya et al., 2011; Winslow et al., 2006). 
Extracellular signal regulated kinase (ERK)-mitogen activated protein kinase (MAPK) 
pathway is another pathway activated downstream of the BCR. The adaptor protein Grb2 
steps into the picture, interacts with the guanine nucleotide exchange factor (GEF) Son of 
sevenless (Sos), and facilitates the activation of ERK through a series of downstream 
signaling steps involving activation of the small G-protein Ras (Coughlin et al,, 2005). 
Additionally, c-Jun N-terminal kinase (JNK) pathway, also a MAPK pathway is activated 









CD19 provides essential co-stimulatory signals. Phosphorylated motifs of CD19 recruit  
signaling proteins, for instance, Phosphoinositide-3-kinase (PI3K) which catalyzes the 
production of membrane bound phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 
facilitates pleckstrin homology (PH) domain mediated recruitment and activation of protein 
kinase B (PKB or Akt) (Okkenhaug & Vanhaesebroeck, 2003). Cell survival is promoted by 
the PKB/Akt activation (Pogue et al., 2000).  
 
DAG and Ca2+ second messengers also activate the canonical NF-κB pathway. Membrane 
bound DAG facilitates the recruitment and activation of protein-kinase C-β 
(PKCβ) (Nishizuka, 1992).  PKCβ  subsequently phosphorylates a protein called CARD-
containing MAGUK protein 1 (CARMA1) (Sommer et al., 2005). CARMA 1 forms part of 
a trimolecular complex with adaptor proteins Mucosa-associated lymphoid tissue lymphoma 
translocation protein 1 (MALT1) and B-cell lymphoma/leukemia 10 (Bcl10). This complex 
is therefore denoted as the CBM complex (Shinohara et al., 2007). Via a poorly understood 
mechanism, the CBM complex recruits the transforming growth factor beta-activated kinase 
(TAK) complex, which further recruits the Inhibitor of κ B kinase (IKK) complex (Wang et 
al., 2001). The IKKβ subunit phosphorylates IκB which marks it for proteasomal 
degradation and releases the NF-κB subunit dimers. Initially sequestered in the cytoplasm, 
bound to IκB, the NF-κB subunits upon release, translocate to the nucleus and activate gene 
transcription. In contrast, non-canonical NF-κB pathway is activated by stimulation of the 
members of the tumor necrosis factor receptor superfamily (TNFR) including CD40, 
Lymphotoxin beta receptor and the B cell activating factor receptor (BAFF) (Coope et al., 
2002). The NF-κB family of transcription factors are crucial regulators of B cell 
proliferation, differentiation and apoptosis. Constitutive NF-κB activation has been found in 
several types of cancers, suggesting their pro-proliferative/anti-apoptotic effects mediate 















Figure 2: Differences in the membrane bound immunoglobulin structures. The differences in the 
structures of the mIg aid mIgM-BCRs and IgG-BCRs in deploying varying signaling modules that exhibit 
differing  immune response intensity. The short cytoplasmic tail of the mIgM-BCR makes it dependent on the 
ITAM motifs of the Igα/Igβ heterodimer for signal transduction and the subsequent Ca2+ mobilization as part 
of the primary immune response. Unlike the mIgM-BCRs, mIgG-BCRs are equipped with an immunoglobulin 
tail tyrosine or ITT motif (enclosed in red square).  Engagement of the mIgG-BCRs results in activation of the 
canonical ITAM-based signaling pathway as illustrated for the mIgM-BCR. This signal is fortified by the 
additional Grb2-Btk mediated signaling from the ITT motif. Thus, mounting the secondary immune response.  
 
Affinity maturation and class-switching modifies the sensitivity and threshold for the 
activation of BCRs and subsequently the intensity and duration of their immune function. 
Naïve B cells mount a primary response marked by moderate serum IgM titers. Post class-
switching and affinity maturation,  this initial encounter results in B cells that can confer 
long-lived humoral memory, called the memory B cells expressing cell surface IgG-BCRs 
(Figure 2). Re-encounter with the same antigen then initiates the secondary response, marked 
by early onset and significantly high serum levels of high affinity, class switched, IgG 
antibodies (Arpin et al., 1995). Therefore, the BCR-isotype is critical in determining the 
nature of immune response mounted by the B cell. 
 
1.3 Members of the  BCR transducer complex: steady complex formation of SLP65 
with CIN85 and/or CD2AP 
After the processes of affinity maturation and class-switching equip a B cell with a 
functional, antigen-specific receptor, the intracellular effector proteins come into the picture 
and provide necessary regulation checkpoints. The ultimate physiological action of the B  
cells is  thus dependent on the three aspects coming together in a carefully regulated manner.  
 





The BCR-proximal and distal effector proteins carefully regulate the downstream signaling 
events, enabling either signal relay, amplification or inhibition of the signal. These critical 
steps of signal regulation are marked by protein complexes. Protein complexes constitute 
members that can either covalently modify the substrates with their enzymatic activities, or, 
a second class of molecules call the adaptor proteins, which instead provide a platform to 
facilitate interactions between various molecules (Gavin et al., 2006). Adaptor proteins lack 
inherent enzymatic activity but enable multimolecular complex formations with their 
versatile protein-protein and/or protein-lipid interaction domains  (Kurosaki T., 2002). The 
adaptor proteins are thus capable of controlling the spatio-temporal dynamics of the 
signaling events during B cell activation (Good et al., 2011). 
 
 SLP65: the master regulator  
As depicted in the canonical BCR-signaling scheme (Figure 1), SLP65 phosphorylation and 
the assembly of the Ca2+ initiation complex is a critical upstream signaling step for the 
various signaling pathways mentioned. Also called the central B cell linker (BLNK) or B 
cell adaptor containing SH2 domain (BASH), SLP65 is expressed exclusively in B cells. It 
was identified by virtue of being heavily phosphorylated upon BCR activation (Bonilla et 
al., 2000; Fu et al., 1998; Goitsuka et al., 1998; Wienands et al., 1998). SLP65 is essential 
for both B cell development and activation. However, SLP65-deficiency presents varying 
phenotypes depending on the species under investigation. Mice lacking SLP65 exhibit 
partial hinderance to B cell development, with the presence of immature B cells that show 
reduced Ca2+ mobilization compared to the wildtype mice (Hayashi et al., 2000; Jumaa et 
al., 1999; Minegishi et al., 1999; Xu et al., 2000). In humans, the absence of SLP65 results 
in severe immunodeficiency manifested as agammaglobulinemia (Minegishi et al., 1999). 
Finally, in chicken DT40 cells, SLP65 absence renders B-cells incapable of exhibiting BCR-
mediated Ca2+ mobilization (Ishiai et al., 1999).  
 
As depicted in the figure 3, SLP65 consists of a positively charged N-terminal region 
proposed to form a leucine zipper capable of anchoring SLP65 molecule to the membrane. 
The N-terminus thus serves as an important lipid interaction moiety, facilitating the 
membrane recruitment of SLP65 (Engelke et al., 2014). Adjacent to the basic amino- 







Figure 3: Modular architecture and interactions between SLP65 and/or CD2AP. SLP65 molecule consists 
of a positively charged N-terminal region, constituting the basic effector domain (labelled as +, encompassing 
the first 50 amino acids). This is followed by the proline rich region with the proline rich motifs marked as 1, 
2, 3 and 4. Proline rich motifs (PRM) 1, 2 and 3 are of the PXXXPR type and PRM 4  is of the PXPXXR type. 
These proline rich motifs serve as binding sites for CIN85 and CD2AP. The C-terminus of the protein 
constitutes the SH2 domain. CIN85 and CD2AP exhibit high structural and sequence similarity, with the 
domain organization of the two proteins being almost identical. In each protein, there are three N-terminal SH3 
domains, followed by a proline-rich region and a C-terminal coiled-coil domain (labelled as CC). 
 
terminal domain is the central proline rich region (PRR). This region consists of several 
tyrosine residues which serve as targets for phosphorylation, in addition to the multiple 
proline rich motifs (PRM) (Oellerich et al., 2011). The PRM 1, 2, and 3 are of PXXXPR 
type, providing docking sites for CIN85 and/or CD2AP (Oellerich et al., 2009). In terms of 
functional significance, the second and third PRM are critical for CIN85 interaction while 
the PRM 1 is dispensable (Oellerich et al., 2011). Recently, an additional PRM (PRM 4) of 
PXPXXR type has been identified by Prof.  Griesinger’s group which has been tested in 
vitro to be capable of participating in the interaction of SLP65 with CIN85. The functional 
significance of the SLP65-CIN85 interaction mediated by the PRM 4 within B cells is 
however, yet to be established. Finally, the C-terminus of SLP65 consists of an SH2 domain 
which is responsible for facilitating the recruitment of SLP65 to the plasma membrane and 
the BCR, where it binds the non-ITAM pY204 in the tail of Igα (Abudula et al., 2007; Engels 









 CIN85/CD2AP: the loyal assistants.  
CIN85 was first identified as the Cbl-interacting protein of 85 kDa by isolating and cloning 
the gene from humans (Take et al., 2000) and subsequently as Ruk (regulator of ubiquitous 
kinase) (Gout et al., 2000), SETA (SH3 domain-containing gene expressed in tumorigenic 
astrocytes) from rats (Borinstein et al., 2000) and SH3KBP1 (SH3 domain kinase binding 
protein 1) when isolated from the mice (Narita et al., 2001). CD2AP is another adaptor 
protein that displays high structural and sequence similarities to CIN85 (Dustin et al., 1998). 
It was originally identified as a scaffold protein required for organization of the 
immunological synapse between a T lymphocyte and an antigen-presenting cell (Dustin et 
al., 1998). Due to their sequence and structural similarities, CIN85 and CD2AP form part of 
a family of adaptor proteins, officially designated as the CIN85/CMS family, CMS being 
the human homologue of the mouse CD2AP gene (Dikic I., 2002) 
The overall domain organization of CIN85 and CD2AP is identical. Homology searches 
based on the deduced amino acid sequence gave information about the domain organization 
of CIN85 (Take et al., 2000). At the amino-terminus, CIN85 consists of three SH3 domains 
known to mediate protein–protein interactions by binding to proline-rich motifs. Adjacent 
to the third SH3 domain is a proline-rich region, providing potential recognition sites for 
other SH3-domain containing proteins. The C-terminal domain assumes a coiled-coil 
structure (Figure 3).  It has been established that this domain facilitates homo-
oligomerization of CIN85 or hetero-oligomerization with CD2AP,  due to its ability to form 
stable coiled-coil trimers (Kühn J., 2015).  
 
CIN85 and CD2AP adaptor proteins exhibit multi-functional properties. The SH3 domains 
can bind to atypical proline rich motifs of the PXXXPR type (Kowanetz et al., 2003; Kurakin 
et al., 2003). CIN85 also presents multiple functional protein isoforms (created as splice 
variants or from internal promoter usage) capable of regulating numerous cellular processes 
in cell-type specific or developmental stage specific manner (Dikic I., 2002; Havrylov et al., 
2009). For a long time after discovery, majority of CIN85 studies focussed on its function 
in the epidermal growth factor receptor (EGFR) signaling (Soubeyran et al., 2002). Upon 
EGFR activation, CIN85 mediates clustering of c-Cbl and endophilin and thus drives  
 





receptor internalization. Similar receptor downregulation mechanisms have been reported 
for other receptor tyrosine kinases (Petrelli et al., 2002; Soubeyran et al., 2002; Szymkiewicz 
et al., 2002). Similarly, CD2AP is a rather well-established regulator of kidney glomerular 
functions in mice and humans. CD2AP-deficient mice, exhibit a strong nephrotic defect 
(Shih et al., 1999). 
 
Few studies report the function of CIN85 and CD2AP in immune cells. It has been shown 
that CIN85 and CD2AP can interact with a transmembrane protein called CD2 in T cells 
(Dustin et al., 1998; Tibaldi & Reinherz, 2003). CIN85 links CD2 to cytoskeleton owing to 
its interaction with the actin capping protein CapZ. This implicates CIN85 in promoting 
cytoskeletal reorganization events upon TCR-activation (Hutchings et al., 2003). 
Additionally, CD2AP-deficient T cells showed prolonged phosphorylation of the Zap70 
kinase and Ca2+ mobilization, associated with a defect in TCR degradation (Lee et al., 2003). 
In mast cells, CIN85 has been shown to downregulate signaling via the FcεRI due to receptor 
internalization, thus inhibiting degranulation of mast cells (Molfetta et al., 2005).  
 
Recently, it was shown that mice with T cell-specific deletion of CIN85 or CD2AP, showed 
hyperresponsiveness  in terms of proliferation and IL-2 production, thus implicating CIN85 
in inhibitory interactions (Kong et al., 2019). Along similar lines, another report suggests 
negative regulatory functions of CIN85 in B cells. CIN85 has been reported to interact with  
SHIP-1 that downregulates PIP3 levels in B cells (Damen et al., 2001) and thereby inhibits 
BCR signaling. Furthermore, CIN85 has also been described to inhibit Syk and PLCγ2 
phosphorylation in addition to the reduction in BCR-induced Ca2+ mobilization (H. Niiro et 
al., 2012). 
 
In stark contrast to these reports, the positive regulatory significance of the constitutive  
interaction between SLP65 with CIN85 and/or CD2AP has been established by our group. 
SLP65-deficient DT40 cells and primary B cells when expressing a SLP65 variant with the 
CIN85 and CD2AP docking sites disrupted showed a defect in BCR-stimulated Ca2+ 
mobilization (Oellerich et al., 2011). Additionally, in the absence of the steady interaction 
in these cells, SLP65 showed reduced phosphorylation.  
 
 





Furthermore, these cells showed a defect in the NF-κB signaling pathway upon BCR-
activation (Oellerich et al., 2011). Similar reports appeared from studies in the primary 
mouse B cells deficient in CIN85, where the NF-κB pathway activation upon BCR 
stimulation is reduced. It was shown that CIN85 links BCR to IKKβ activation. Interestingly, 
in this report, the BAFF-mediated non-canonical NF-κB pathway was shown to remain 
unaffected (Oellerich et al., 2011).  
 
Patients exhibiting antibody deficiency were identified by our group and analyzed in 
collaboration with the Human genetics department, Göttingen. These male siblings were 
diagnosed with antibody deficiency marked by diminished serum antibody titers to various 
extents. This resulted in common consequences of recurring severe bacterial infections. The 
older brother with all immunoglobulin isotypes reduced, died of a septic shock. The younger 
brother shows reduced IgM and IgG4 levels and served as the index patient.  The whole 
exome sequencing analysis (WES) revealed that the patients harboured an inactivating 
germline deletion within the CIN85 gene on the X chromosome. However, in contrast to the 
reduced serum antibody levels, the peripheral B cell and T cell compartments of the younger 
sibling appeared undisturbed. Despite the previously mentioned involvement of 
CIN85/CD2AP in T-cell functions, analysis of the of the patient’s T cell responses showed 
wild type levels of activation upon TCR/CD28 stimulation. This is in contrast to the patients´ 
B cells, which showed reduced Ca2+ mobilization and a defect in NF-κB activation upon 
BCR stimulation, indicating that the deletion mutation resulted in B-cell specific effects. 
Additionally, no such defects were seen upon activation of the B cells by Phorbol myristate 
acetate (PMA), CD40 ligand or CpG oligodeoxynucleotides, which is indicative of a role of 
CIN85 specifically downstream of the BCR (Keller et al., 2018). The study of these patient-
conditions, calls for a system that could provide molecular details about how these proteins 
work inside the cells, which was one the aims of my thesis.  
 
To encapsulate, several studies suggest an involvement of CIN85/CD2AP adaptor proteins 
in a plethora of intracellular signaling pathways. These include imparting both positive and 
negative regulatory functions. More specifically, with respect to B cells, equipped with the 
adequate understanding of the significance of the preformed transducer complex, it became 
necessary to explore the molecular mechanism propelling these signaling events. 
 





1.4 Scope of the thesis  
Based on the reported significance of SLP65-CIN85 interaction in B cell development and 
function in mice and humans, we were interested in exploring the facets of this complex-
assembly and its functions further. 
 
To accomplish our main objectives, I pursued the following specific aims: 
 
• Generation of CIN85-deficient human and mouse B cell lines, followed by 
subsequent deletion of CD2AP from the two respective cell lines, making use of the 
CRISPR/Cas genome editing technology. The cellular system thus created, was used to 
conduct genetic and biochemical functional assays to elucidate the role of these adaptor 
molecules in both BCR-proximal and downstream signaling events. 
 
• Making use of the aforementioned cell lines to employ mass spectrometric analyses 
for the identification of thus far unreported interaction partners of SLP65, facilitated by the 
absence of the significant constitutive binding partners, CIN85 and CD2AP. 
 
• Combining the techniques of structural biology with mutational analyses, and 
imaging approaches, to garner an understanding of the nature and biophysical properties of 





Chapter 2: Results  
2.1 CIN85 and CD2AP regulate BCR-proximal signaling events 
As mentioned in the previous section, considering the significance of SLP65/CIN85 
interaction observed in the patients and the mouse models, it became necessary to create 
model systems from established B cell lines, the use of which could provide mechanistic 
details for the function of CIN85/CD2AP adaptor proteins within B cells. In this regard,  I 
used CRISPR/Cas9-gene editing technique as described in Cong & Zhang, 2014 to first 
knock-out CIN85 from the human DG75 B cell line. DG75 human burkitt’s lymphoma cell 
line originated from a boy and the CIN85 gene locus on account of being positioned on the 
X-chromosome proved helpful such that disruption of only one allele resulted in successful 
inactivation of the gene. For the purpose of designing CRISPR-guide sequences, exon 3 in 
the CIN85 gene was targeted. This exon is present in almost all CIN85 isoforms (Figure 4, 
A) and is early in the order amongst exons in the genomic sequence such that an INDEL 
mutation mediated by Cas9-cleavage resulted in a premature stop codon early enough for 
the translated protein product to be rendered functionally inactive.  
  
After electroporation with the CRISPR-constructs and subsequent cell sorting for GFP 
(simultaneously encoded by the CRISPR-construct) positive cells, the genomic DNA was 
isolated and a segment of exon 3 encompassing the targeted sequence was amplified via 
PCR. Subsequent cleavage with the restriction endonuclease HpyCHV, the binding site of 
which overlapped with the Cas9 cutting site, indicated the successful activity of 
CRISPR/Cas9 system in the transfected cells. For explanation: Cas9 cleavage-mediated 
insertion/deletion mutation modified the binding site of the HpyCHV restriction 
endonuclease, thus preventing DNA restriction digestion in cells successfully targeted by 
the CRISPR/Cas system. The DNA bands thus appearing at a different positions, post 
agarose gel electrophoresis, when compared to the unmodified DNA of the homogenous 
population of parental cells (Figure 4, B). Post subsequent sub-cloning, the clones were 
screened for CIN85-absence via western blotting. The CIN85-deficient clones are depicted 
in figure 5, A. It was additionally observed that knocking-out CIN85 does not disturb the 
expression levels of CD2AP and SLP65 proteins (Figure 5, A).  
 









Figure 4: Exon 3 in the CIN85 gene was targeted for CRISPR/Cas9-mediated gene editing.  
(A) Upper panel: Domain architecture of the predominant CNI85 isoforms in B cells. CIN85-l is the long 
isoform of CIN85 consisting of 3-SH3 domains on the N terminus followed by a proline rich region and a 
coiled-coil domain on the C-terminus. CIN85-ΔA lacks the first SH3 domain (labelled as SH3A). Lower 
panel: schematic representation of the CIN85 genomic locus indicating the targeted exon and the nucleotide 
sequence against which the guide sequence was designed (B) To test cleaving activity mediated by the 
CRISPR/Cas constructs transfected into the cells, amplification of the Exon 3 was carried out via PCR. The 
PCR amplicon was subjected to restriction digestion with the HpyCH4V endonuclease, the binding site of 
which overlapped with the Cas9 cutting site. Once modified due to Cas9 induced insertion/deletion mutation, 
the target site undergoes modification, affecting restriction endonuclease’s binding capacity, thus resulting in 












Figure 5: Identification of CIN85-KO clones of the human DG75 cell line. (A) Cleared cellular lysates of 
DG75 parental and putative CIN85-KO clones were tested for CIN85 expression via western blot analyses 
using antibodies against CIN85. Similarly, CD2AP and SLP65 expression levels were compared using 
antibodies against the respective proteins. Actin was used as the loading control.  (B) The histogram represents 
the flowcytometric analyses of surface BCR levels, detected using anti-hIgM-CY5 antibody (C) Sequencing 
results indicating the target site modification compared to the sequence of the wild type CIN85 allele have been 
depicted, along with the changes that the sequence modification confers to the biological product 
 
CIN85 has been known to be indirectly associated with RTKs via its interaction with Cbl 
such that it promotes their internalization upon receptor ligation. I proceeded to check 
whether deletion of CIN85 could also impact the cell surface expression levels of BCRs in 
the resting cells. It was observed that the expression of mIgM-BCR in the representative 
CIN85-deficient clones was similar to that of the parental cells (Figure 5, B),  indicating that  
 





wild-type levels of cell surface IgM is expressed in CIN85-KO DG75 cells. This additionally 
ruled out the possibility of clonal variations or CRISPR/Cas off target affects that could 
impact the cell surface BCR levels. The deletion of CIN85 in the knock-out clones was 
additionally validated at the level of nucleotide sequence. The sequencing results of one such 
representative CIN85-KO clone, clone #23 revealed insertion of a nucleotide at the Cas9 
cleavage site which in turn resulted in a shift in the translation reading frame, thus rendering 
a premature stop codon (Figure 5, C).  This clone represents the DG75 CIN85-KO cells that 
were used during the course of the study.  
 
To monitor the effect of CIN85 expression on BCR-mediated Ca2+ mobilization, I 
transduced the CIN85-KO cells with constructs as depicted in figure 6, A. I tested three 
CIN85-KO clones for their capacity to support Ca2+ flux while expressing either wild-type 
or full length CIN85 protein (wt), a variant of CIN85 lacking its C-terminal coiled-coil 
domain (ΔCC), or while expressing EGFP (mock) protein.  
 
Interestingly, it was observed that at high stimulating F(ab )́2  concentrations, the impact of 
CIN85-presence or absence on BCR-mediated Ca2+ mobilization was negligible. The 
CIN85-KO cells promoted Ca2+ flux to the same extent as the cells expressing wild type 
CIN85, ∆CC variant or the mock. However, at low stimulating F(ab ́)2  concentrations, it was 
observed that the CIN85 expression governs the onset as well as the amplitude of Ca2+ 
mobilization. This was observed in all three CIN85-deficient clones that were tested. CIN85 
thus significantly increased the capacity of cells to get activated, supporting Ca2+ influx 
levels that were higher than those in cells lacking CIN85 or expressing the ∆CC variant. 
CIN85 expression reduces the stimulation threshold for BCR-and thus positively regulates 
Ca2+ mobilization in human DG75 B cells. 
 
The signaling defect seen for the ∆CC variant of CIN85 is plausible, because the C-terminal 
coiled-coil domain of CIN85 is the critical effector unit of CIN85. It mediates homo (with 
other CIN85 molecules) and hetero-oligomerization (with proteins like CD2AP), to form 
clusters of CIN85, thereby increasing the local concentration of its interaction partner SLP65 
and an inability to do so, hampers the SLP65-mediated Ca2+ mobilization in the cells. 
 
 






Figure 6: CIN85 expression in cells enables them to respond to low stimulating F(ab ́)2  concentrations.    
(A) CIN85-KO DG75 clones: # 23, 34 and 15 were transduced with citrine-tagged CIN85-wt (green line),  
 





variant of CIN85 lacking the C-terminal coiled-coil domain  (blue), or the EGFP/mock protein (yellow) as 
depicted. The Ca2+ influx in the transduced citrine positive cells of clone #23 was monitored upon stimulation 
with (B) 5 µg/ml α-human IgM F(ab )́2 or (C) 0.5 µg/ml α-human IgM F(ab )́2  via flow cytometry. (D-E) The 
Ca2+ influx in transduced CIN85-KO clones #24 and #15 was monitored upon stimulation with 0.5 µg/ml α-
human IgM F(ab )́2  by flow cytometry. (F) The western blot depicts the expression levels of  CIN85 or its 
ΔCC-variant in the transduced cells of CIN85-KO clone #23.  (G) The histograms confirm similar expression 
levels of the  citrine-tagged proteins along with the EGFP-mock protein in the respective cell populations. (H-
I) The western blots depict the expression levels of  CIN85 or its variant in the retrovirally transduced 
populations of clone #34 and clone #15.  
 
 
Identical strategy of CRISPR/Cas-mediated gene disruption was applied to the Exon 3 of 
mouse CIN85 encoding gene in the IIA1.6 cell line. IIA1.6 cells are a descendant of the 
more commonly used A20 murine cell line. It is important to note that unlike DG75 cells 
that express cell surface IgM-BCRs, IIA1.6 cells express the class-switched IgG-BCRs 
(refer section 1.1) representing memory B cells – a different B cell developmental stage. As 
mentioned in the earlier, the structural differences between the two BCR molecules equips 
them to mount immune responses of varying intensities, with IgM transducing the signal via 
the ITAM motif. The IgG in addition to mounting the canonical ITAM mediated response 
also harbours an ITT motif that plays additional role in BCR-mediated signaling within the 
B cells. It is of significance therefore, to be able to compare the signaling events in these 
mIgG-expressing cells with those of DG75 cells expressing cell surface IgM.   
 
The guide sequence was selected using the previously-mentioned CRISPR online tool. The 
Cas9-cleaving activity in the transfected cells was tested by treating the Exon 3 PCR 
amplicon with the restriction enzyme HpyCHV, the binding site of which overlapped with 
the cleavage site of the Cas9 enzyme, resulting in its inability to bind to the modified binding 
site, thus ensuring successful Cas9-mediated cleavage. After western blot screening to 
identify CIN85-KO clones, the knock-outs were validated at the nucleotide-sequence level. 
Unlike DG75 cell line, there are two X chromosomes in IIA1.6 cells harbouring two CIN85 
coding alleles. In the representative sequencing results from CIN85-KO clone #22, there 
were two mutations identified, corresponding to the two alleles: one was the 25-nucleotide 
deletion surrounding the Cas9 cutting site, and the other was the insertion of a nucleotide at 
the said position. Both resulted in a shift of the translation reading frame which in turn 
resulted in a premature stop codon, giving rise to a functionally inactive, truncated protein 
product.  
 







Figure 7: Creation and identification of CIN85-KO IIA1.6 clones using CRISPR/Cas9-mediated gene 
editing technology and western blot analyses. (A) Upper panel: Domain architecture of CIN85 isoforms 
found in IIA1.6 cells. Lower panel: schematic representation of the CIN85 genomic locus in mice indicating 
the targeted exon and the nucleotide sequence against which the guide sequence was designed.  
 





(B) To test cleaving efficiency mediated by the CRISPR/Cas constructs transfected into the cells, the PCR 
amplicon was cleaved with the restriction enzyme HpyCH4V, the binding site of which overlaps with the Cas9 
cutting site. Once modified due to Cas9 induced insertion/deletion mutation, the restriction endonuclease is 
unable to bind to its target site. (C) Cleared cellular lysates of IIA1.6  parental and putative CIN85-deficient 
clones were tested for CIN85 expression via western blot analyses using antibodies against CIN85. Similarly, 
CD2AP and SLP65 expression levels were compared using antibodies against the respective proteins. Actin 
was used as the loading control.  (D) Sequencing results indicating the target site modification compared to the 
sequence of the wild type CIN85 allele have been depicted along with the changes they confer to the protein 
product. 
 
On monitoring the Ca2+ mobilization capacity of the cells transduced with either CIN85-wt, 
CIN85-ΔCC or the EGFP-mock, similar results, as for the DG75 cells were observed (Figure 
8). At high stimulating concentrations, no difference in Ca2+ flux onset or amplitude were 
observed amongst the different cell populations. However, at 10-fold lower stimulating 
F(ab ́)2 concentrations, the wild type or full length-CIN85 expressing cells were capable of 
mounting a stronger Ca2+ response. Additionally, similar to the respective constructs 
expressed in DG75 cells, the CIN85-ΔCC variant expressing IIA1.6 cells mediated signaling 
to the same level as the CIN85-KO cells or KO cells expressing the mock protein, indicating 
that similar to the observations made in the human DG75 cells, this variant is incapable of 
promoting Ca2+ signaling in the mouse IIA1.6 cells.  
 
The observations made have critical physiological implications. They depict that B cells 
when expressing full length CIN85 protein are better capable of sensing even the small doses 
of circulating antigen concentrations, get activated and have the capacity to mount a robust 
immune response. This would aid early clearance of the pathogen from the system before it 
renders any significant harm to the host. Furthermore, the combined observations made in 
the human and mouse CIN85-deficient cell lines corroborate the Ca2+ phenotype observed 
in the case of the immunodeficient patients (explained in section 1.3.2) wherein a similar 
Ca2+ defect was observed for the patient’s B cells when compared to the healthy controls.   
It has been reported that CD2AP bears high structural and functional similarity to CIN85 
(Section 1.3.2). It has a domain architecture almost identical to that of CIN85 (with 
additional actin binding motifs), and similar to its counterpart, CD2AP is a ubiquitously 
expressed protein that has been implicated in several cell surface receptor-associated 
functions. We were therefore curious to test if within B cells, CD2AP provides functional 
redundancies in terms of the intracellular signaling.  
 







Figure 8: CIN85 mediated positive regulatory effects on Ca2+ mobilization in IIA1.6 mouse B cells are 
similar to DG75 cell. (A) CIN85-KO IIA1.6  clone #22 was transduced with citrine-tagged CIN85-wt (green 
line), variant of CIN85 lacking the coiled-coil domain  (blue), or the EGFP/mock protein (yellow) as depicted. 
The Ca2+ influx in transduced citrine-positive cells  was monitored upon stimulation with (B) 5 µg/ml α-mouse 
IgG F(ab ́)2 or (C) 0.5 µg/ml α-mouse IgG F(ab )́2  via flow cytometry. (D) The western blot depicts the 
expression levels of  CIN85 or its variant in the transduced populations of clone #22, along with the expression 
levels of CD2AP, detected with antibodies directed against the respective proteins. (E) The histogram confirms 
similar expression levels of the citrine-tagged proteins and the EGFP-mock protein in the respective cell 
populations as specified.  
 
To this extent, CRISPR/Cas9-mediated gene editing was performed to target Exon 2 of the 
gene encoding CD2AP within the CIN85-KO DG75 cells and the clones with the combined 
absence of CIN85 and CD2AP were identified. The targeting and the protein-deletion 
confirmation steps have been explicitly explained in the figure 9.  
 

















Figure 9: Exon 2 of CD2AP  in human CIN85-KO DG75 B cells was targeted for CRISPR/Cas9-mediated 
gene disruption and the CIN85/CD2AP-dKO clones were identified. (A) Upper panel: Domain 
architecture of the CD2AP protein in human DG75 B cells. Similar to CIN85, it consists of 3-SH3 domains on 
the N terminus followed by a proline rich region and a coiled-coil domain on the C-terminus. However, unlike 
CIN85, CD2AP has 4 actin binding motifs (blue circles). Lower panel: schematic representation of the CD2AP 
genomic locus indicating the targeted exon and the nucleotide sequence against which the guide sequence was 
designed (B) To test cleaving efficiency mediated by the Cas9 enzyme encoded by the CRISPR constructs 
transfected into the cells, amplification of the Exon 2 was carried out via PCR. The PCR amplicon was 
subjected to restriction digestion with the enzyme Taqα1, the binding site of which overlapped with the Cas9 
cutting site, thus enabling effective testing for the success of the transfected CRISPR/Cas9 system (C) Cleared 
cellular lysates of DG75  parental and putative CIN85/CD2AP-dKO clones were tested for CIN85 and CD2AP 
expression via western blot analyses using antibodies against CIN85 and CD2AP respectively. Similarly, 
SLP65 expression levels were compared using antibodies against the respective proteins. Actin was used as 
the loading control.  (D) Sequencing results indicating the target site modification compared to the sequence 
of the wild type CIN85 allele have been depicted along with the changes they confer to the protein product. 
(E) The western blot depicts the CIN85 and CD2AP expression levels in parental and CIN85-KO DG75 clone 
as well as the CIN85/CD2AP-dKO cells that were retrovirally transduced with constructs expressing either 
CIN85-wt, the ΔCC variant of CIN85, CD2AP or the EGFP-mock. Antibodies directed against CIN85 and 
CD2AP were used and the detection of actin served as the loading control.  
 
On comparing the Ca2+ mobilization capacity of CIN85-deficient and CIN85/CD2AP-
double deficient cells, it was observed that knocking-out CD2AP from previously CIN85-
depleted cells, does not reduce the Ca2+ flux levels further to a significant extent. A very 
mild effect on Ca2+ mobilization capacity of the cells lacking both the proteins was observed. 
On the contrary, when these cells were transduced to over-express the wild type CIN85 and 
CD2AP proteins, it was observed that BCR-mediated Ca2+ mobilization capacity of the cells 
significantly increases compared to the cells that lacked both CIN85 and CD2AP (Figure 10, 
A-D).  
 
The patients and the mouse models discussed previously additionally exhibited a B cell-
specific defect in the BCR-mediated NF-κB pathway activation. I therefore proceeded to 
monitor BCR-distal signaling events in these cells by monitoring the phosphorylation of 
IκBα which is part of the activation of NF-κB pathway and  ERK  (Figure 10, E). I observed 
that while the phosphorylation of ERK appeared to be dependent on the stimulating antigen 
concentrations, only the stimulation independent, basal levels of phosphorylated IκBα were 















Figure 10:  Over expression of CD2AP in CIN85/CD2AP-double deficient DG75 B cells improves their 
Ca2+ signaling capacity. (A) CIN85/CD2AP-double deficient DG75 cells were transduced with citrine-
tagged CIN85-wt (green line), CD2AP  (orange), or the EGFP/mock protein (yellow) as depicted. (B) The Ca2+ 
influx in the CIN85-KO and CIN85-dKO was monitored upon stimulation with 0.5 µg/ml α-human IgM F(ab )́2   
 





via flow cytometry. (C) The Ca2+ influx in the CIN85-dKO expressing either wild type CIN85, wild type 
CD2AP or EGFP was monitored upon stimulation with 0.5 µg/ml α-human IgM F(ab )́2  via flow cytometry. 
(D) The histogram confirms similar expression levels of the citrine-tagged proteins and the EGFP-mock protein 
in the respective cell populations as specified. (E) Cell lysates were prepared after stimulation of 
CIN85/CD2AP-dKO cells either expressing wild type CIN85 or EGFP with indicated concentrations of α-
human IgM F(ab )́2 . IκBα phosphorylation was analysed by SDS-PAGE and immunoblotting with antibodies 
against phospho-IκBα  (p-IκBα) or total IκBα. ERK phosphorylation was also monitored with antibodies 
directed against phospho-ERK (p-ERK). Actin served as the loading control.  
 
The BCR-activated ERK phosphorylation levels were also similar in the observed cell 
populations. Therefore, despite the significant differences in the levels of  Ca2+  influx in the 
CIN85 expressing and the CIN85-deficient cells, similar signaling differences were not 
observed for the activation of NF-κB pathway and the MAPK/ERK pathway. This hinted 
towards  possible redundancies conferred by additional signaling elements in the cells. 
Moreover, it was concluded that DG75 cells, despite serving as a well-established cellular 
system to monitor Ca2+ signaling, do not serve as a suitable model system to study the 
activation of BCR-mediated the NF-κB pathway. 
 
Although extremely robust in terms of culture growth and maintenance, even the established 
cell lines can present inconsistencies in signaling observations owing to multiple factors. To 
rule out any impact of the inadvertent differences in sample handling or culture conditions 
of the independent cell populations, I additionally monitored the Ca2+ signaling in cells that 
were cultured in a co-culture set up, as explained below (Figure 11). The CIN85/CD2AP-
dKO cells which lacked any fluorescently tagged proteins were cultured in a 1:1 ratio with 
the cells either expressing cintrine-tagged wild type-CIN85 or citrine-tagged ΔCC-variant 
of CIN85 or EGFP/mock protein. Therefore, each pair of cell populations analysed (dKO 
with transduced-dKO) came from the same culture dish, underwent the same sample 
preparation procedures and were subjected to stimulation in the same sample tube, thus 
giving more reliable Ca2+ flux measurement results. In this way the previous Ca2+ influx 
differences in the CIN85 expressing cells, compared to the cells expressing ΔCC-variant of 
CIN85 or the mock control, were corroborated to confirm a role of CIN85 in BCR-mediated 












Figure 11: CIN85 expression positively regulates the Ca2+ influx levels in a co-culture setup. The co-
culture set up consisted of DG75 CIN85/CD2AP-dKO cells mixed in equal proportions with the dKO-
transfectants expressing exogenous citrine-tagged CIN85 (A), ΔCC variant of CIN85 (B) or the EGFP-mock 
(C). The cells were co-cultured under optimum culture conditions and the Ca2+ flux monitored after 
stimulation with 0.5 µg/ml α-human IgM F(ab ́)2 via flowcytometry. (G-I) The histograms confirm equal 
proportion of the two cell populations at the time of Ca2+ flux measurement in the co-cultured system.  
 
To draw species-comparative conclusions, identical CRISPR/Cas9-mediated gene editing 
was performed for the CD2AP locus in the CIN85-KO mouse IIA1.6 cells  (Figure 12), the 
dKO clones were identified and validated by sequencing. Monitoring the Ca2+ mobilization 
in these cells, the observations that were made for the DG75 cells were corroborated.  
 
 






Figure 12: Exon 2 of CD2AP in mouse CIN85-KO IIA1.6 cells was targeted for CRISPR/Cas9-mediated 
gene editing and CIN85/CD2AP-dKO cells were identified. (A) Upper panel: Domain architecture of the 
CD2AP protein in mouse IIA1.6 cells Lower panel: schematic representation of the CD2AP genomic locus 
indicating the targeted exon and the nucleotide sequence against which the guide sequence was designed  
 





(B) To test cleaving efficiency mediated by the Cas9, the amplification of the Exon 2 was carried out via PCR. 
The PCR amplicon was subjected to restriction digestion with the enzyme Sfc1, the binding site of which 
overlapped with the Cas9 cutting site, resulting in incomplete digestion of the DNA sample. (C) Cleared 
cellular lysates of IIA1.6 parental and putative CIN85/CD2AP-dKO clones were tested for CIN85 and CD2AP 
expression via western blot analyses using antibodies against CIN85 and CD2AP respectively. Similarly, 
SLP65 expression levels were compared using antibodies against the respective proteins. Actin was used as 
the loading control.  (D) Sequencing results indicating the target site modification have been depicted along 
with the changes they confer to the protein product. 
 
 
IIA1.6-dKO cells showed a very mild effect of CD2AP deletion on Ca2+mobilization, 
however the over-expression of CD2AP significantly increased the Ca2+ flux level in the 
cells, almost to the level of CIN85 expressing cells.  (Figure 13, B).  Additionally, unlike the 
DG75 cells, the IIA1.6 cells showed a stimulation dependent activation of the NF-κB 
pathway. There was almost no phosphorylated IκBα (pIκBα) detected for the unstimulated 
cells and upon stimulation with increasing concentrations of the antibody, the levels of 
pIκBα also increased. A moderate reduction in pIκα levels was observed for the dKO cells 
when compared to the cells expressing wild type CIN85. In the case of ERK 
phosphorylation, the results were similar to those observed for the DG75 cells.  
 
Equipped with these KO and dKO cells, I proceeded further to perform genetic and 
biochemical functional assays to explore the function of CIN85  in B cells.  








Figure 13: Over expression of CD2AP in CIN85/CD2AP-dKO IIA1.6 B cells significantly improves their 
Ca2+ signaling capacity. (A) CIN85/CD2AP-dKO IIA1.6 cells were transduced with citrine-tagged CIN85-
wt (green line), CD2AP  (orange), or the EGFP/mock protein (yellow) as depicted. (B) The Ca2+ influx in the 
CIN85-KO and CIN85/CD2AP-dKO cells was monitored upon stimulation with 0.5 µg/ml α-mouse IgG 
F(ab ́)2  via flow cytometry. (D) The Ca2+ influx in the CIN85-dKO cells expressing either wild type CIN85, 
wild type CD2AP or EGFP was monitored upon stimulation with 0.5 µg/ml α-mouse IgM F(ab ́)2  via flow 
cytometry. (D) The histogram confirms similar expression levels of the citrine-tagged proteins and the EGFP-
mock protein in the respective cell populations as specified. (E) Cell lysates were prepared after stimulation of  
CIN85/CD2AP-dKO cells either expressing wild type CIN85 or EGFP with indicated concentrations of              
 





α-mouse IgG F(ab )́2 . IκBα phosphorylation was analysed by SDS-PAGE and immunoblotting with antibodies 
against phospho-IκBα  (p-IκBα) or total IκBα. ERK phosphorylation was also monitored with antibodies 
against phospho-ERK (p-ERK). Actin served as the loading control.  
 
 The human CIN85/CD2AP-dKO cell line serves as a model system to test the 
functional relevance of mutations found in CIN85 encoding gene of 
immunocompromised patients.  
After corroborating the Ca2+-defect phenotype of the patients mentioned in chapter 1 with 
the help of knock-out cell lines I generated, the subsequent course of action was to screen 
for any additional mutations in CIN85 gene that render the biological product functionally 
inactive in humans. I proceeded to test the signaling capacity of the prevailing variants of 
CIN85 reported in several patients. We identified these patients in collaboration with the 
human genetics department in Göttingen. All the reported patients are males and exhibit an 
immunocompromised condition, akin to the male siblings mentioned previously. Each of the 
three amino acid substitutions identified are positioned such that, they present a high 
probability of affecting the function of CIN85.  The Q541E substitution falls close to PRR 
before the C-terminal coiled-coil domain. This mutation was reported in two patients. The 
T266I mutation was reported in 4 patients and lies right at the beginning of the third SH3 
domain. Finally, the R413Q mutation which was reported in 2 patients is present in the 
LSRPGALPRR sequence in the proline rich region which is an optimum SH3 binding site. 
We were interested in screening for mutations that inhibited or modified, in any manner, the 
interaction of CIN85 with SLP65 thereby influencing the Ca2+ mobilization. The 
CIN85/CD2AP-dKO cells that I generated from the human DG75 cell line in the previous 
section thus served as a proficient cellular system to screen for such mutations and thus 
indicate their clinical significance with regard to the immunocompromised condition of the 
patients.  
 
I therefore utilised the technique of site directed mutagenesis to create constructs that 
mimicked the abovementioned patient mutations. I then retrovirally transduced each of these 
constructs into the CIN85/CD2AP-dKO DG75 cells and monitored BCR-stimulated Ca2+ 
mobilization at 0.5 and 0.1 µg/ml α-human IgM F(ab ́)2 concentrations.  
 
 






Figure 14: Testing the functional relevance of point mutations in the gene encoding CIN85 reported in 
immunocompromised patients. CIN85/CD2AP-dKO DG75 cells were transduced with citrine-tagged 
CIN85-wt (green line), Q541E mutant (purple), T266I mutant (yellow line), R413Q mutant (blue line) or 
L619K mutant (red line) as depicted. The Ca2+ influx in transduced and sorted citrine positive cells upon 
stimulation with (A-D) 0.5 µg/ml α-human IgM F(ab )́2  or (E-H) 0.1µg/ml α-human IgM F(ab )́2 was monitored 
by flow cytometry. (I-L) The histograms confirm similar expression levels of the two citrine-tagged proteins 
in the respective cell populations. 
 





Additionally, I expressed an L619K variant of CIN85 as a negative control: the NMR studies 
in Kühn et al., 2016 established that replacing the hydrophobic residue Leu619 with the 
hydrophilic residue lysine impacts the stability of the coiled-coil domain, such that,  the 
trimerization gets disrupted.  
 
In my results, I observed that none of these mutations hampered the capacity of CIN85 to 
promote calcium mobilization (Figure 14). It appeared that these mutations are “silent” or 
“quiet” mutations that although change the amino acid sequence of the protein, fail to alter 
the biological function. The CIN85 variants function similar to wild type-CIN85 in terms of 
SLP65 clustering, mediating Ca2+ flux to the wild type levels. The negative control showed 
a decreased calcium flux compared to wild type-CIN85.  
 
These point mutations therefore, cannot be directly implicated for the immunocompromised 
condition of the patients, as these CIN85 variants do not show any defect in the capacity of 
B cells to get activated upon BCR-stimulation. Presently it is difficult to rule out the 
possibility of additional/alternative combination of factors which could be responsible, 
however these results demonstrate that inefficient CIN85-mediated clustering of the master 
regulator SLP65 can be ruled out.  
 
 CIN85 influences the plasma membrane localization of PKCβ upon BCR-
mediated stimulation of cells 
Beyond its well-established role in constitutive interaction with the key adaptor protein 
SLP65 and driving its multimerization to subsequently regulate its capacity to conduct Ca2+ 
mobilization, CIN85 has been implicated to play a role in NF-κB pathway activation in B 
cells (Keller et al., 2018, Kometani et al., 2011). Earlier we attempted to investigate this by 
monitoring the effect of the absence or presence of CIN85 on the extent of phosphorylation 
of IκBα, a key signaling step in the pathway in the established cell lines. Considering the 
sequence of events in the NFκB signaling pathway, this step appears way downstream of the 
BCR-antigen ligation. We were therefore interested in setting up a read-out system at a 
relatively upstream-level that could give us hints as to the involvement of  
 






Table 1: PKCβII interactome analysis in the human DG75 B cell line. Strep-tagged version of human 
PKCβII was introduced into the DG75 cells via electroporation. The selected positive clones were mixed to 
avoid clonal variations and were cultured in SILAC medium containing heavy amino acids Lysine D4 (Lys+4), 
Arginine 13C6 (Arg+6). For control, DG75-wt cells were cultured in SILAC medium containing light amino 
acids. The two cell populations were stimulated for 5 minutes with α-human IgM F(ab ́)2 fragments and the 
lysates from these cells were subject to affinity purification by streptavidin-coated beads. The purified light 
and heavy labeled samples were pooled in a 1:1 ratio and subsequently analyzed by mass spectrometry. The 
mass  spectrometry  analysis  and  preliminary  data  processing  was  done  in  collaboration  with  the  
Proteomics Core Facility of University Medicine Göttingen. Data are from one experiment. 
 
CIN85 in the NF-κB pathway.  Studying PKCß activation served as an appealing option in 
this regard owing to several reasons. Multiple studies have highlighted a crucial role of 
PKCß in NFκB pathway activation specifically in B cells. It has been shown that IκB 
degradation is abrogated in PKCß-deficient B cells activated by IgM ligation but not in the 
case of stimulation with CD40 (Saijo et al., 2002; Su et al., 2002). This bears stark 
resemblance to the CIN85-deficient patient’s B cells where, BCR stimulation of the primary 
B cells could not induce NF-κB activation whereas other stimuli (PMA, CD40) did (Keller 
et al., 2018). 
 
Our very initial endeavour was to get a more exhaustive view of the interaction partners of 
PKCβ in B cells in an attempt to check for its interaction with CIN85. For this, a strep-tagged 
version of PKCβII was used to pull down interaction partners from stimulated SILAC-
labeled B cell lysates, which were then identified via mass spectrometry (done in 
collaboration with the Proteomics Core Facility of University Medical Center Göttingen).  
 





Table 1 enlists the prominent interaction partners with around 2.0-fold enrichment ratio for 
proteins that fulfilled the significance conditions. It is important to note that these proteins 
include both direct and indirect interaction partners. Additionally, however, in these affinity 
purification procedures, certain labile protein interactions can be lost owing to the use of 
harsh detergent conditions. Although mentioned in the list, CIN85 does not make the 2.0-
fold enrichment ratio cut-off which suggests that it is unlikely that CIN85 is involved in 
direct interaction with PKCβII in these cells or if it does, the interaction is highly unstable 
and cannot be studied by means of conventional affinity purifications.  
 
Our next technical approach was to retrovirally transduce the citrine-tagged version of 
protein kinase C β II (PKCβII) into DG75 cells. Of the two isoforms PKCβI and PKCβII 
which are simultaneously expressed in several B cell lines, DG75 cells lack the expression 
of PKCβII. This allows us to study the functioning of the exogenously expressed citrine-
tagged variant of the protein without the interference from any endogenously expressed 
protein. Expression of the citrine-tagged version of PKCβII in parental DG75 cells allowed 
for visualizing of the protein within the cell with confocal laser scanning microscopy (Figure 
15, A). PKCβII is localized in the cytoplasm in resting B cells and undergoes translocation 
to the plasma membrane upon BCR stimulation (Su et al., 2002). This could be confirmed 
by our confocal microscopy experiments that showed a ring like appearance on recruitment 
of the citrine-tagged protein to the plasma membrane upon BCR-mediated activation, the 
ring being most prominent around 30 secs of stimulation showing maximum recruitment, 



























Figure 15: BCR-mediated activation induced PKCβII plasma membrane translocation in DG75 cells. 
(A) Parental DG75 cells were retrovirally transduced with Citrine-tagged human PKCβII. The cells were then 
sorted to achieve a homogenous sub-cell population consisting of cells with similar expression levels of   
 





exogenously expressed Citrine-tagged PKCβII. The cells were subsequently subjected to confocal laser 
scanning microscopy and the plasma membrane localization of the Citrine-tagged PKCβII was monitored in 
resting cells and cells stimulated with 10µg/ml α-human IgM F(ab )́2 fragments, over the time course of 2 
mins. These cells were then analysed at the AMNIS imaging flow cytometer to subsequently make quantitative 
measurements. After the data acquisition with imaging flow cytometer, the analysis was performed using the 
co-localization wizard of the Image Data Exploration and Analysis Software from AMNIS called IDEAS® 
according to the given analysis strategy: (B) the dot plot represents the gating strategy used to identify single 
cells. The single cells are further subjected to above depicted gating strategy to obtain cells falling within a 
specific range of their Citrine-fluorescence intensity. Subsequently, the similarity feature of the wizard is used 
to specifically compare the co-localization of Citrine tagged-PKCßII and the membrane dye to define 
membrane recruitment. Similarity >1.5 between membrane dye and PKCßII represented cells with membrane 
localized PKCβII. (C) These histograms depict the resting and stimulated cell populations respectively where 
the contrast Morphology >9 equals PKCßII membrane recruitment. (D) BCR activation-mediated PKCßII 
membrane recruitment kinetic profile for DG75 parental cells. The cells were stimulated with 10µg/ml α-
human IgM F(ab )́2 fragments. The Y-axis indicates the percentage of cells with membrane localized PKCßII. 
(E) Effect of increasing concentration of α-human IgM F(ab )́2 fragments on PKCßII membrane recruitment 
in parental DG75 cells. The cells were stimulated for 30 secs. The Y-axis indicates the percentage of cells with 
membrane localized PKCßII. Standard deviations were calculated with recruitment values from 3 biological 
replicates, each further representing three technical replicates.*.These experiments were conducted in 
collaboration with Dr. Marcel Liebick.  
 
Confocal microscopy, although a conventionally trusted imaging technique spatially 
restricts the visual observations to merely a few cells at a time and does not give a 
quantitative indication of the behaviour of cells in a given population. To overcome this 
challenge, I collaborated with a Post Doc. colleague from my department Dr. Marcel Liebeck 
and decided to shift to a technically more sophisticated system that combines the power of 
imaging and flowcytometry called, Amnis® imaging flow cytometer, a high-throughput 
system that allowed us to make quantitative, statistically robust measurements in addition to 
the conventional imaging studies. A detailed analysis strategy explains the selected 
parameters and the gating system used to quantify the cells for their PKCβII membrane 
recruitment (Figure 15, B and C).  
 
 





Figure 16: CIN85 can regulate PKCβII membrane translocation upon B cell activation. DG75 parental 
cells(blue), CIN85-KO cells(red), CIN85/CD2AP-dKO cells(grey), cells expressing the C-terminal deletion 
variant of CIN85(yellow) and finally cells overexpressing the wt-version of CIN85(green) were tested for the 
extent of PKCβII membrane translocation upon stimulation with increasing doses of α-human IgM F(ab )́2 
fragment concentrations. Each cell population was stimulated for 30 secs. The analysis was performed using 
the co-localization wizard of the Image Data Exploration and Analysis Software from AMNIS called IDEAS® 
with which the percentage of cells displaying co-localization of the Citrine fluorescence signal with the signal 
from the plasma membrane stain CellMask™ was quantified. The Y-axis indicates the percentage of cells with 
membrane localized PKCßII. Standard deviations were calculated with recruitment values from 3 biological 
replicates, each further representing three technical replicates. ** P ≤ 0.01. These experiments were conducted 
in collaboration with Dr. Marcel Liebick. 
 
Initial experiments with the parental DG75 cells established that PKCβII membrane 
recruitment response from the majority of cells in a population occurs 30 secs post-
stimulation (Figure 15, D). Additionally, the membrane localization is antigen-concentration 
dependent with increasing percentage of cells showing PKCβII recruitment with increasing 
concentrations of α-human IgM F(ab ́)2 fragments (Figure 15, E).The established AMNIS 
imaging flowcytometry-based PKCßII membrane translocation assay allowed for 
comparative quantitative visualization of membrane recruitment of the citrine-tagged protein 
in multiple cell-populations. Therefore, I used this assay to test the PKCßII plasma 
membrane localization in CIN85-deficient cells and the several transduced sub-cell lines that 
were created. It was observed that a significantly higher proportion of cells were capable of 
recruiting PKCßII to their plasma membrane when over-expressing CIN85-wt as compared 
to those expressing either the ∆CC-variant or the EGFP mock (Figure 16). This indicated 
that the presence of CIN85 is capable of impacting the plasma membrane translocation of 
























 Ibrutinib downregulates BCR-mediated NF-κB pathway activation in IIA1.6 
cells but not in DG75 cells. 
I made use of ibrutinib, an irreversible inhibitor of Bruton’s tyrosine kinase (integral member 
of the calcium initiation complex) to confirm its capacity to inhibit Ca2+ mobilization and 
test if it affects the canonical NF-κB pathway activation in the CIN85/CD2AP-dKO DG75 
and IIA1.6 cells (Figure 17). As expected, ibrutinib successfully inhibits Ca2+ flux in both 
DG75 and IIA1.6 cells almost entirely. This result also highlights the fact that there is no 





Figure 17: Ibrutinib inhibits Ca2+ signaling in DG75 and IIA1.6 cells but has a varying effect on NF-κB 
pathway activation in the two cell lines. CIN85/CD2AP-dKO DG75 cells (A) or IIA1.6 cells (B) were  
 





treated with 1µM Ibrutinib prior to stimulation with 5 µg/ml α-IgM F(ab ́)2 for DG75 and α-IgG F(ab )́2 for 
IIA1.6 cells and the Ca2+ flux was monitored by flowcytometry. (C) Cell lysates were prepared after 
stimulation of respective cell lines either treated with 1µM Ibrutinib (+I) or not treated with Ibrutinib (-I) and 
IκBα phosphorylation was analyzed by SDS-PAGE and immunoblot analyses with antibodies against phospho-
IκBα (pIκBα). The upper panel shows the immunoblot post longer time exposure and high contrast settings 
and the lower panel shows the same blot with lower contrast settings. Actin was used as the loading control. 
 
For both IIA1.6 and DG75 cells, there is stimulation independent, similar basal levels of 
phosphorylated IκBα which is unaffected by ibrutinib’s presence. There is a spike in the 
levels of pIκBα upon BCR-stimulation in IIA1.6 cells, indicating activation of the canonical 
NF-κB pathway which was not the case for DG75 cells. This indicated that apart from basal 
levels, there is was no additional activation of the pathway upon the stimulation of cells.   
 
 The CIN85-KO impact on the viability of cells in a co-culture set up is specific to 
the cell line being investigated. 
An additional method of monitoring the involvement of these adaptor proteins in 
intracellular signaling pathways was to test the effect of their depletion on cell viability and 
cell growth.  This would give an indication of their involvement with regard to the low level, 
constitutive signaling in the basal state (tonic signaling) that does not require BCR-mediated 
signals but are required for survival of the cells. The main advantage of this set-up however, 
was that it aims to partially mimic the B cell compartment of the mother of the patients 
harbouring deletion in their CIN85 gene, positioned on the X chromosome (see chapter 1). 
Considering the Lyon Hypothesis and the random X chromosome inactivation, it is 
reasonable to believe that the mother’s B cell compartment is a heterogenous mixture of 
CIN85 expressing and CIN85-deficient B cells, and under competitive conditions, 
differential survival advantages might play a role in determining which population takes 
over and mediates the immune responses.  
 
Equipped with the human and mouse knock-out B cell lines which could be transduced to 
express fluorescent-tagged proteins, we devised a means to monitor the viability of cells and 
the rate of cell growth in the presence or absence of fluorescently tagged-CIN85 expression 
over the course of 4 days in a co-culture set up.  
 
 





For this, I mixed the CIN85/CD2AP-double deficient cells lacking any fluorescence and 
cells reconstituted with citrine-tagged CIN85 in equal proportion and monitored the changes 
in the abundance of the non-fluorescent and fluorescent populations of the cells in the culture 
at 24 hrs time points (Figure 18). The cell count comparisons for the non-florescent and 
fluorescent cells (high citrine), gave indication of the abundance of each of the two cell 
populations in the culture at that time point.  
It was observed that for the human DG75 B cells (Figure 18), there was no difference in the 
viability or the rate of cell growth for the dKO and citrine-tagged CIN85 expressing 
populations of cells in the culture and that an equal abundance of the two populations was 
maintained over the course of 72 hours.  
 
Unlike the DG75 cells, contrasting observations were made for the mouse IIA1.6 cells 
(Figure 19). After 24 hrs of co-culture, cell count peak for the cells lacking CIN85 (non-
fluorescent cells) started to reduce in comparison to the cells expressing citrine-tagged 
CIN85.  Post 72 hrs of co-culture, the differences in the abundance of the two cell 
populations became more prominent. This indicates that CIN85 in the mouse IIA1.6 cells 
somehow impacts the tonic signals that serve a maintenance function. Biologically, this 
holds significance as it hints to the possibility that, over the years, one B cell compartment 
takes over the other in a heterogenous peripheral B cell population of the mother, because 





















Figure 18: Absence of CIN85 and CD2AP in DG75 cells does not impact the cell viability or growth rate 
in a co-culture set up. The co-culture set up consisted of DG75 CIN85/CD2AP-dKO cells mixed in equal 
proportions with the DG75 dKO-transfectants expressing exogenous citrine-tagged CIN85 and co-cultured 
under optimum culture conditions. The fraction of non-fluorescent (dKO) and fluorescent (expressing citrine-













Figure 19: Absence of CIN85 and CD2AP in IIA1.6 cells has a negative impact on the cell viability or 
growth rate in a co-culture setup. The co-culture set up consisted of IIA1.6 CIN85/CD2AP-dKO cells mixed 
in equal proportions with the IIA1.6 dKO-transfectants expressing exogenous citrine-tagged CIN85 and co-
cultured under optimum culture conditions. The fraction of non-fluorescent (dKO) and fluorescent (expressing 
citrine-tagged CIN85) cells was monitored via flowcytometry over the course of 72 hrs  at every 24 hrs time 
point.   
 
 





 Combined deletion of CIN85 and CD2AP does not influence the stimulation 
triggered-BCR internalization. 
In several reports, CIN85 has been implicated in receptor downregulation functions. In fact, 
for several years after discover, the function of CIN85 that received the most widespread 
attention was its capacity to facilitate ligand induced internalization of receptors such as the 
EGFR, thus dampening the effector functions (Soubeyran, et al., 2002). Moreover, with the 
ability to interact with actin capping proteins and CD2AP being especially equipped with 
actin binding sties, it was fair to assume that CIN85 and CD2AP could connect the cell 
surface BCRs to components of the actin cytoskeleton, playing an important role in receptor 
endocytosis. We were therefore curious to check if the above-mentioned receptor 
internalization activity of CIN85 is specific with regard to the receptor tyrosine kinases, or 
if similar effects are exerted on the cell surface BCRs.   
 
I tested this in both human and mouse established B cell lines using the CIN85/CD2AP-dKO 
cells I had generated. I retrovirally transduced the double deficient-cells with constructs 
encoding either wild type CIN85 or the mock control EGFP. This system could give us 
reliable information about the impact of the presence or absence of CIN85 on antigen 
induced BCR internalization without any possible compensatory effects of CD2AP. I then 
proceeded to analyse the BCR levels using flowcytometry, prior (0 min) and post antigen 
stimulation over the course of 120 mins (Figure 20).  The cells were appropriately stimulated 
with either biotinylated anti-human IgM or anti-mouse IgG which initiated the BCR 
internalization. The remaining BCRs localised on the cell surface were stained with APC 
fluorophore-conjugated streptavidin. Monitoring the levels of the residual BCRs left at the 
B cell surface at several time points after stimulation in this manner, gives us an indirect 












The DG75 and IIA1.6 cells, after stimulation for 120 mins showed a decrease in surface 
BCR levels of up to 70 and 80% respectively, compared to the unstimulated cells. 
Additionally, the expression of CIN85 in the CIN85/CD2AP-dKO cells does not alter the 
kinetics of BCR internalization. This indicates that perhaps in B cells, CIN85 is prioritised  




Figure 20: Deletion of CIN85 and CD2AP does not influence BCR internalization. (A) DG75 or (B) IIA1.6 
CIN85/CD2AP-dKO cells expressing either wild type CIN85 (green) or EGFP mock (yellow) were analyzed 
for stimulation-mediated receptor internalization by staining of the remnant cell surface IgM for DG75 cells 
or IgG for IIA1.6 cells over the course of 120 mins. The percentage values of the surface BCR are relative to 
those of the resting cells and were calculated form the mean fluorescence intensity of the APC fluorophore-
conjugated streptavidin that bound to biotinylated α-human IgM or α-mouse IgG primary antibodies. The 0 
min time point depicts the total BCR levels on the surface of resting cells followed by 30, 60 and 120-min time 
points post stimulation with 1 µg/ml primary antibody. Standard deviations were calculated from three 
independent experiments.  
 
 








Figure 21: Experimental outline for mass-spectrometric identification and relative quantification of all 
the PXXXPR ligands.   





(A) Domain architecture of SLP65 with the four atypical proline/arginine motifs (indicated 1-4) and their 
amino-acid sequences in human and murine SLP65. (B) Amino-acid sequence of the N-terminally biotinylated 
peptides encompassing the central proline/arginine motif of SLP65 as either wild-type (Test peptide) or 
binding-inactive version (Control peptide) for affinity purification experiments. (C) The binding capacity of 
the peptides was tested by subjecting the lysates from IIA1.6 parental or CIN85/CD2AP dKO cells to affinity 
purification tests with the aforementioned peptides, followed by SDS-PAGE and immunoblotting analyses of 
the purified proteins. The blot was probed with antibodies against known interaction partners namely, CIN85, 
CD2AP and a co-purification protein CapZ-α1. (D) Schematic representation of the independent forward and 
reverse pull-down approaches for comparative analyses of the ligands binding to the biotinylated peptides. In 
the forward pull-down experiment, the test peptides are immobilized on streptavidin beads and incubated with 
the lysate from DG75 CIN85/CD2AP dKO cells or IIA1.6 CIN85/CD2AP dKO cells metabolically labelled 
with heavy (Lys+8/Arg+10) amino acids. For control, the control peptides are incubated with lysate from the 
respective cell lines cultured in light (Lys+0/Arg+0) SILAC medium. The heavy and the light purified 
proteins(eluates) were mixed at a 1:1 ratio, digested with trypsin and identified by quantitative LC-MS/MS 
analysis using MaxQuant software. In the reverse pull-down experiment, the test peptides are incubated with 
the light lysate and the control peptides are incubated with the heavy lysate. The subsequent steps for protein 
purification and mass-spectrometric analyses were the same as in the forward SILAC-labeling experiment. 
Binding candidates give large H/L enrichment values in the forward experiment and small H/L enrichment 
ratios in the reverse experiment.  
 
2.2 Amphiphysin 2/Bin 1 can bind atypical SH3-binding motifs on SLP65 
In Oellerich et al. 2011, it was established that steady ligands CIN85 and CD2AP constitute 
the stimulation-independent preformed signalosomes. Moreover, the interaction was shown 
to be highly selective, with the central proline/arginine motif of SLP65 exclusively purifying 
CIN85 and CD2AP from the B cell lysates.  
 
The human and mouse CIN85/CD2AP-double deficient cell lines I created gave us an 
opportunity to study additional, thus far unreported, PXXXPR ligands that bind to SLP65 
via the same interaction module as the CIN85 and CD2AP adaptor proteins. Figure 21, B 
shows the synthetic biotinylated peptides encompassing the central proline/arginine motif of 
SLP65 and the surrounding amino acids to purify its interaction partners from the human 
and mouse B cell lines. These peptides are referred to as the test peptides. Additionally, 
peptides carrying a mutated version of the proline/arginine motif designed to be incapable 
of interacting with CIN85 and CD2AP was used as a control and these peptides are referred 
to as the control peptides. I then proceeded to confirm the capacity of the peptides to interact 
with known interactors CIN85 and CD2AP and their close associates like the CapZ-α1 in 
both the parental cells and the CIN85/CD2AP-double deficient cells. I also confirmed the 
binding incompetence of the control peptides (Figure 21, C). 
 
 














Figure 22: Interaction partners of the central proline/arginine motif of SLP65 in human DG75 B cells. 
The scatter plot represents the values of ‘heavy’ versus ‘light’ ratio of enrichment (H/L) of the identified and 
quantified proteins, plotted against their intensity measured in the mass spectrometer. These values are plotted 
on logarithmic scales in the forward SILAC-labeling experiment (A) and the Reverse SILAC-labeling  
 





experiment (B) respectively. Proteins with a normalized H/L ratio of about 2.0-fold or greater in the forward 
labeling-experiment and about -2 or smaller in the reverse labeling-experiment are highlighted with their gene 
names. Identified proteins significant only in forward SILAC-labeling experiment are highlighted in blue, those 
identified and significant only in reverse SILAC-labeling experiment are highlighted in green and the identified 
proteins satisfying significance requirements in both forward and reverse pull-down experiments are 
highlighted in red. (C) The results from the forward and reverse pull-down approaches are combined and the 
identified proteins fulfilling significance requirements in both the approaches are highlighted in red with their 
gene names. (D) Proteins highlighted in (C) are represented in tabular format with values for normalized H/L 
ratio, number of peptides, gene name, protein ID and protein name. The mass spectrometry analyses and 
preliminary data processing was done in collaboration with the Proteomics Core Facility of University 
Medicine Göttingen. 
 
Finally, the figure 21, D, illustrates the experimental scheme used for purification, detection 
and subsequent analyses of the binding partners. Forward and reverse pull-down approaches  
for the comparative analyses of the ligands binding to the biotinylated peptides was adopted 
In the forward pull down experiment, the binding proficient test peptides were immobilized 
on streptavidin beads and incubated with the lysate from DG75 CIN85/CD2AP-dKO cells 
or IIA1.6 CIN85/CD2AP-dKO cells metabolically labelled with heavy amino acids after 
being cultured in the heavy SILAC medium. For control, the binding incompetent peptides 
were incubated with lysate from the respective cell lines cultured in light SILAC medium.  
The heavy and the light purified proteins (eluates) were then mixed at a 1:1 ratio and 
analysed via mass spectrometry (done in collaboration with the Proteomics Core Facility of 
University Medical Center Göttingen). 
 
In the reverse pull-down experiment, the test peptides were incubated with the light lysate 
and the control peptides are incubated with the heavy lysate. The subsequent steps for protein 
purification and mass-spectrometric analyses were the same as in the forward SILAC-
labeling experiment. Binding candidates give large H/L enrichment values in the forward 
experiment and small H/L enrichment ratios in the reverse experiment. Therefore, combined 
together, the forward and reverse labeling approaches can provide more reliable 
quantification results.  
 
I considered the proteins that satisfied significance conditions and presented a 2.0-fold and 
higher enrichment ratio in the forward SILAC labeling approaches and proteins that 
presented a -2.0-fold and smaller enrichment ratio values in the case of reverse SILAC 
labeling approach. The results of the mass spectrometry analyses are presented in the figure 
22 for DG75 cells and figure 23 for the IIA1.6 cells respectively.  
 

















Figure 23: Interaction partners of the central proline/arginine motif of SLP65 in murine IIA1.6 B cells. 
The scatter plot represents the values of ‘heavy’ versus ‘light’ ratio of enrichment (H/L) of the identified and  
 





quantified proteins, plotted against their intensity measured in the mass spectrometer. These values are plotted 
on logarithmic scales in the forward SILAC-labeling experiment (A) and the Reverse SILAC-labeling 
experiment (B) respectively. Proteins with a normalized H/L ratio of about 2.0-fold or greater in the forward 
labeling-experiment and about -2 or smaller in the reverse labeling-experiment are highlighted with their gene 
names. Identified proteins significant only in forward SILAC-labeling experiment are highlighted in blue, those 
identified and significant only in reverse SILAC-labeling experiment are highlighted in green and the identified 
proteins satisfying significance requirements in both forward and reverse pull-down experiments are 
highlighted in red. (C) The results from the forward and reverse pull-down approaches are combined and the 
identified proteins fulfilling significance requirements in both the approaches are highlighted in red with their 
gene names. (D) Proteins highlighted in (C) are represented in tabular format with values for normalized H/L 
ratio, number of peptides, gene name, protein ID and protein name. The mass spectrometry analyses and 
preliminary data processing was done in collaboration with the Proteomics Core Facility of University 
Medicine Göttingen. 
 
In both the cell lines, the forward and reverse labeling approaches confirmed that 
Amphiphysin 2 also called the Bridging integrator-1 (Bin1) was purified along with 
proline/arginine motif and consistently showed the highest enrichment in both the cases.  
 
As depicted in the figures above, SH3KBP1 or CIN85 was also detected in the Mass  
spectrometry results, despite the cellular system created with the intention to be deficient in 
both CIN85 and CD2AP. There was no CD2AP detected which meant that the CRISPR/Cas-
mediated deletion of CD2AP was successful. The detection of CIN85 however, indicated a 
remnant/residual CIN85 expression in these cells owing possibly to alternative splice 
variants or variants of CIN85 expressed due to the usage of alternative internal promoters,  
rendering isoforms of CIN85 that expressed in much smaller quantity than the more 
significant wild type version. 
 
It is however, imperative to note that despite the leaky expression of this CIN85 variant, 
Amphiphysin 2/Bin 1 is still observed to be the more significant interaction partner owing 
to significantly reduced level of CIN85 expression. Amphiphysin 2/Bin 1 has been described 
to have an N-terminal BAR domain with a predicted coiled-coil structure and C-terminal 
SH3 domain (Sakamuro et al., 1996) via which it can possibly interact with the atypical 
proline rich motifs of SLP65. 
 
I then attempted to validate the mass spectrometry results biochemically, by testing for the 
binding of Amphiphysin 2/Bin 1 to the central proline rich motif of SLP65 taking the 
approach of western blotting (Figure 24). I made use of the same control and test peptides 
as mentioned above and purified binding partners from cell lysates of both parental IIA1.6 
cells and the IIA1.6 CIN85/CD2AP-dKO cells. 







Figure 24: Amphiphysin 2 variants are capable of interacting with the isolated central proline rich motif 
of SLP65. Parental mouse IIA1.6 B cells or IIA1.6 CIN85/CD2AP-dKO cells were lysed and subjected to 
affinity purification experiments with the test or the control peptides. Obtained proteins were analyzed by 
immunoblotting with antibodies directed against Amphiphysin 2, CIN85 and CD2AP. 
 
 
The prominent bands seen on the blot for the eluate for binding proficient peptide treated 
with the dKO cell-lysate confirmed this interaction. Moreover, relatively faint bands seen in 
the eluate lane for the test peptide treated with the paternal cells’ lysate indicate a 
competition of Amphiphysin 2 for the same binding site with the adaptor proteins CIN85 
and CD2AP, such that, CIN85 and CD2AP are the significantly stronger interaction partners. 
The significance of these findings, in context of the structural properties of Amphiphysin 2 









2.3 SLP65 and CIN85 micro-clusters phase separate into signaling competent 
complexes  
In the previous sections, it was established that CIN85 is capable of reducing the stimulation 
threshold for BCR-mediated Ca2+ signaling in human and mouse B cells. Moreover, 
comparative Ca2+ flux analyses of the CIN85-deficient B cells transfected with either wild 
type-CIN85 or the ΔCC-deletion mutant of CIN85 indicated that the effector functions of 
the CIN85 protein emanate from its C-terminal coiled-coil domain.  This is in conjunction 
with the previously established findings by our department, where it was shown that the 
intracellular localization directed simultaneously but independently by both CIN85 
interaction and the N terminus of SLP65 is essential for SLP65 function in B cells 
(Engelke et al. 2014). This revealed a two-fold regulation mechanism deployed to carefully 
control the SLP65 activation. We were interested in exploring these facets further: 
 
 Introduction to phase separation: SLP65-CIN85 interaction mediates the liquid-
liquid phase-separation of the two proteins in vitro   
During the course of our collaboration with the Prof. Griesinger’s group, we tried to 
understand the underlying biophysical mechanism for CIN85-mediated multimerization 
based micro-clusters of SLP65. It was seen that when SLP65 and CIN85 are mixed in 
equimolar concentrations in vitro, they reorganise into tiny phase-separated droplets. 
 
Following were some of the fascinating in vitro observations made (Figure 25 and Figure 
26), I went on to work with genetic culture systems that allowed mutational analyses to test 
if these observations also held true in live cells, connecting the ability of phase separation 
with the signaling capacity in B cells.  
 
 In the in vitro analyses it was found that the concentration threshold for this phase separation 
was governed by the trimerization capacity of CIN85 and the presence of lipid vesicles. 
SLP65 underwent phase-separation with the CIN851-333 construct lacking its C-terminal 
coiled-coil domain, hence monomeric, at and above 60 μM concentration of both proteins  
 





(Figure 25, A). The concentration for phase separation was reduced to 10 μM when SLP65 
was mixed with the CIN85Δ57 construct, lacking a 57 amino acid segment in the middle but 
capable of efficient Ca2+ mobilization. Finally, it was seen that the threshold concentration 
for phase-separation is reduced even further when small unilamellar vesicles (SUVs) were 





Figure 25: Phase separation of SLP65 with CIN85 and SUVs. A mixture of varying concentrations of Atto 
430LS-tagged SLP65 molecule encompassing the N-terminus and the proline rich motifs with the equal 
concentrations of either (A) CIN851-333 i.e. CIN85 lacking the C-terminus, (B) CIN85Δ57, or (C) CIN85Δ57 and 
1 mM of SUVs was observed under the confocal microscope. Concentrations of CIN85Δ57 refer to the 
monomeric concentration. Figure provided by Dr. Leo Wong. 
 
What was striking was that the concentration for this phase-separation i.e. 0.5 µM is similar 
to the physiological concentrations of SLP65 and CIN85 inside the DG75 human B cells 
(data not shown). This gave us the hint that SLP65 and CIN85 could coalesce into liquid-
liquid phase-separated droplets inside the cells creating membrane-less compartments that 
serve to promote biochemical reactions for signaling.  
 
 





The results in previous section showcased that the presence of SUVs significantly reduced 
the threshold concentrations such that SLP65 and CIN85 could phase separate at 
physiological concentrations. It was thus interesting to explore if the vesicles were a part of 
these phase separated droplets. For this, cryo-electron tomography studies were conducted 
in collaboration with Dr. Philipp Erdmann at the Max Planck Institute in Munich. The 
technique involved vitrification of the phase-separated droplets to faithfully preserve the 
molecular structures and the subsequent three-dimensional imaging by electron tomography. 
This shed light at the molecular assembly of the various components of the droplets.  
 
 
A                                                                                       B 
   
 
Figure 26: Vesicles are present in the phase-separated SLP65-CIN85 droplets in vitro indicating a 
tripartite phase-separation. (A) Cryo-electron tomograph of the droplets A mixture of 1 μM of SLP65 and 1 
μM of CIN85Δ57 together with 1 mM of SUVs was placed on a carbon grid and plunged frozen and subjected 
to Cryo-ET analyses. The cryo-tomogram represents a droplet and in yellow is the 3D rendering of the vesicles 
(B) Histogram depicts the distances between vesicles. The most populated distance is at 22 nm, the average is 
at 19.5 nm ± 0.1 nm. Figure provided by Dr. Philipp Erdmann. 
 
The tomograms showed vesicles distributed inside the phase-separated droplets (Figure 26, 
A) with the average distance between the vesicles being 22nm (Figure 26, B). Interestingly, 









indeed, the phase separation in vitro is tripartite, involving CIN85, SLP65 and the vesicles. 
To test if a similar model of tripartite phase-separation holds true for signaling elements 
inside B cells, such that the phase-separated SLP65, CIN85 and cellular vesicles constitute  
a functional module for B cell signaling, I used the CIN85-deficient DG75 and IIA1.6 B 
cells transduced with citrine-tagged CIN85 and the samples are currently in the process of 
being subjected to similar cryo-ET based studies.  
 
 Replacing the N-terminus of SLP65 with CIN85-CC circumvents the need for 
SLP65 vesicle targeting and interaction with CIN85 
As previously mentioned, B cells deploy a dual mechanism to regulate the SLP65 function. 
N-terminally truncated SLP65 is unable to undergo membrane translocation and shows 
abrogated Ca2+ mobilization upon BCR-mediated B cell activation (Engelke et al. 2014). On 
the other hand, preventing the interaction between SLP65 and CIN85 by destroying the 
CIN85-SH3 domain docking proline rick motifs (PRMs) on SLP65 in turn increases the 




Figure 27: CIN85 SH3 domains bind promiscuously to SLP65. Paramagnetic relaxation enhancement 
(PRE) of the assigned 3 SH3 domains of CIN85 induced by SLP65(40-330) spin labelled at the indicated 
positions. The PRE-profiles show the promiscuous binding of the three SH3 domains to the four proline-rich 
motifs for (PRMs) of SLP65. Figure provided by Dr. Leo Wong. 





In the experiments thus far, SLP65 was thought to interact with CIN85 through PRM1,2 and 
3 individually (refer Figure 3 in introduction), of which the PRM 2 and 3 have been the 
critical players (Oellerich et al. 2011; Kühn et al. 2016). However, recently, Leo Wong in 
Prof. Griesinger’s group established, by spin label-assisted paramagnetic relaxation 
enhancement, that the SH3 domains of CIN85 individually bind to four and not just three 
(as previously thought) proline-rich motifs (PRMs) of SLP65 in a promiscuous manner 
(Figure 27). Additionally, a variant of SLP65 where the coiled-coil domain of CIN85 
replaces the N-terminus of SLP65 molecule in which all four CIN85 binding sites (PRM1, 
PRM2, PRM3 and PRM4) were disrupted was incapable of mediating phase-separation in 
vitro. Similar construct with two out of the four CIN85 binding sites disrupted (PRM2 and 
PRM3) however, showed wild type levels of Ca2+ signaling.  This hinted to the possibility 
that perhaps the robust Ca2+ phenotype in cells expressing this chimera, initially thought to 
constitute the minimal-transducer-module for Ca2+ mobilization in B cells (Kühn et al. 
2016), was possibly a result of remnant CIN85 interaction and hence left-over 
multimerization executed by the 4th recently explained unmutated PRM.  
 
To lay these speculations to rest, I created CIN85CC-∆NSLP651,2,3,4 (R-A) variant with 
all the four CIN85 interaction sites mutated and transduced SLP65-deficient DT40 cells with 
it. I additionally expressed SLP65-wt and CIN85CC-dNSLP652,3(R-A) in SLP65-deficient 
cells as controls. SLP65-deficient DT40 cells were transfected with these SLP65-CIN85 
chimeras as portrayed in figure 28, A. Both the constructs, one with two out four CIN85 
interaction sites disrupted and the other with all four CIN85 interaction sites disrupted 
showed Ca2+ influx comparable to the SLP65-wt construct upon BCR-stimulation (Figure 
28, B). Additionally, while the fluorescent speckles in resting cells were more prominent 
and bigger for SLP65-wt construct, the other two constructs were capable of 
undergoing BCR-stimulation induced plasma membrane recruitment much like SLP65-wt. 
This revealed a dominating role for the CIN85-CC whose presence in a SLP65 molecule 
lacking its N-terminus and all known CIN85 interaction sites was indeed sufficient to 
phenocopy the Ca2+ influx of the wild type protein. This also highlights the fact that the  
fourth PRM does not play a more governing role over PRM2 and PRM3 combined for CIN85 
interaction for proper SLP65 functioning.  
 
 







Figure 28: Oligomerization-mediated by the CIN85-CC functionally substitutes SLP65 N-terminus and 
complete CIN85 interaction. 





 (A) Slp65-deficient DT40 cells were transduced with citrine-tagged SLP65-wt or the chimeric proteins 
depicted. Numbers 1,2,3 and 4 depict the individual PRMs with the respective protein sequence of each 
mentioned below the domain architecture of the protein. The C-terminus coiled-coil domain of CIN85 was 
fused either to SLP65-dN-2,3(R-A) variant (red line) or the SLP65-dN-1,2,3,4(R-A) variant (green line). (B) 
The Ca2+ influx in transduced citrine positive cells upon stimulation with 1µg/ml α-chicken IgM F(ab ́)2 was 
monitored by flow cytometry. (C) The histograms confirm similar expression levels of various fusion proteins 
in the respective cell populations. (D) Intracellular localization and membrane recruitment of the chimeric 
proteins 1min after stimulation (2µg/ml α-chicken IgM F(ab )́2) was observed by confocal microscopy. 
 
 Equipping SLP76 with oligomerizing capacity can enable it to participate in Ca2+ 
signaling cascade in B cells 
SLP76 is the T cell paralog of SLP65 in which CIN85 binding sites are entirely absent. When 
expressed in DT40 cells lacking endogenous SLP65 it is incapable of organizing the calcium 
initiation complex and therefore, unable to promote calcium mobilization. In addition, unlike 
SLP65, it does not get recruited to the plasma membrane on activation of B cells (Kühn et 
al., 2016). This shows that wild type SLP76 is incapable of functionally substituting SLP65 
in B cells. Interestingly, on introduction of CIN85 binding sites inherent in SLP65 into 
SLP76, the modified SLP76 variant successfully conducts calcium mobilization (Oellerich 
et al., 2011). To test if mere oligomerization of SLP76-mediated in the absence of CIN85 
interaction is enough to provide it with functions similar to SLP65 in B cells, I worked with 
SLP76 variants fused with the split Venus protein. 
 
Split Venus is eminently deployed in Bimolecular fluorescence complementation (BiFC) 
experiments to study protein-protein interactions. The two halves VN and VC undergo 
covalent interaction when in spatial proximity and regain a conformation that can emit a 
fluorescence signal. I transduced the constructs VN-SLP76 and VC-SLP76 (Figure 29, A) 
created by Julius Kühn either individually or simultaneously in SLP65-deficient DT40 cells 
and monitored the BCR-mediated Ca2+ influx in the transduced cells. This revealed that a 
VN-SLP76 – VC-SLP76 dimer enabled Ca2+ influx comparable to SLP65-wt (Figure 29, B). 
The dimerised SLP76 construct are seen as speckles in the resting cells which get recruited 
to the plasma membrane albeit poorly upon B cell stimulation (Figure 29, C). These results 
indicate that the local enrichment of SLP65 or SLP76 proteins mediated either by the CC-
domain’s oligomerization capacity or the dimerization property of the split Venus  
 





protein dispenses the necessity for direct CIN85 interaction of these proteins for Ca2+ 
mobilization.  
 
      
 
 
                                                   
Figure 29: Dimerization confers SLP76 with the ability to function similar to SLP65. (A) Slp65-deficient 
DT40 cells were transduced with citrine-tagged SLP65-wt or SLP76 protein fused to parts of the Venus protein 
as depicted. VN-SLP76 and VC-SLP76 were transduced individually (yellow and green line) or simultaneously 
(orange line). (B) The Ca2+ influx in transduced cells upon stimulation with 2µg/ml α-chicken IgM F(ab )́2 was 
monitored by flow cytometry. (C) For cells expressing VN-SLP76 and VC-SLP76 simultaneously, 
intracellular localization and membrane recruitment 1min after BCR stimulation (2µg/ml α-chicken IgM 
F(ab ́)2) was observed by confocal microscopy. The Venus fused SLP76 constructs were kindly provided by 
Dr. Julius Kühn. 
 
 Preventing multimerization of CIN85 impedes Ca2+ signaling in B cells 
Building further on the knowledge of the necessity of CIN85 interaction for SLP65 to 
conduct Ca2+ mobilization, I created a set-up to be able to corroborate the previous findings 
but approaching the question from the side of CIN85 this time, instead of SLP65. As 
mentioned in the previous sections, experiments with the minimal-BCR-transducer element  







Figure 30: L619K mutation disrupts the multimerization of CIN85 and abolishes the support it provides 
SLP65 for its function. (A) CIN85/CD2AP-dKO DG75 cells were transduced with citrine-tagged CIN85-wt 
(green line) or the L619K mutant (red line) as depicted. (B) The Ca2+ influx in transduced citrine positive cells 
upon stimulation with 0.5 µg/ml α-human IgM F(ab ́)2 or (C) 0.1µg/ml α-human IgM F(ab )́2 was monitored 
by flow cytometry. (D) The histograms confirm similar expression levels of the two citrine-tagged proteins in 
the respective cell populations. 
 




represented by CIN85-CC-SLP65 fusion proteins have established that CIN85 supports 
SLP65-function in Ca2+ mobilization owing to its C-terminal effector domain. In the 
experiments conducted by Dr. Leo Wong and Dr. Stefan Becker, it was shown, 
through Multiangle laser light scattering and NMR spectroscopy experiments, that this C-
terminal effector domain of CIN85 forms a coiled-coil trimer of high stability (Kühn et al., 
2016). In the same study, NMR analysis showed that the position of Leu619 at the 
hydrophobic interface in the coiled-coil domain is critical for the stability of coiled-coil such 
that on replacing the hydrophobic residue Leu619 with the hydrophilic residue lysine, the 
trimerization gets disrupted. The Mass spectrometric analysis of the recombinant CIN85 
L619K confirm this as this variant is exclusively monomeric in vitro (Kühn et al., 2016).  
 
I mimicked this mutation into the CIN85-wt construct to create a modified CIN85-L619K 
variant and transduced the constructs into CIN85/CD2AP-double deficient DG75 cells that 
I had created previously, as explained in section 1.1 (Figure 30, A). After confirming similar 
protein expression levels for the wild type and L619K-variant of CIN85(Figure 30, D), I 
analyzed the Ca2+ influx in these cells upon stimulation with 0.5µg/ml α-human IgM F(ab ́)2  
and 0.1µg/ml α-human IgM F(ab ́)2  concentrations (Figure 30, B-C) respectively. The Ca2+ 
influx mediated by the CIN85 variant harbouring the L619K mutation was significantly 
impaired in conducting Ca2+ mobilization compared to CIN85-wt at higher stimulating 
antigen concentration (Figure 30, B) and is almost incapable of Ca2+ signaling at lower 
stimulating antigen fragment concentration (Figure 30, C).  
 
This corroborates the structural studies of the coiled-coiled domain of CIN85 thus far and 
underscores the functional significance of this critical amino acid for ensuring CIN85-
mediated support to SLP65 to promote BCR-mediated Ca2+ mobilization in B cells.  
 A crucial balance between the affinity and the functional avidity of SLP65-CIN85 
interaction sites reigns the Ca2+ signaling in B cells.  
After mutational analyses directed towards loss of function of CIN85/SLP65 complexes, we 
focussed on strategies that could possibly enhance their function. A series of previous 
experiments revealed that the PRM2 independently executes primary SLP65-CIN85 
interaction compared to the other PRMs which contribute to the avidity of interaction with  
 





a reduced affinity (Oellerich et al., 2011). We were therefore curious to test the function of 
a SLP65 variant with majority of its PRMs exchanged for the PRM2 resulting in a “super- 
interactor” SLP65 such that the individual PRMs interacted with individual SH3 domains of 
CIN85 with a much greater affinity. For this, I transduced SLP65-deficient DT40 cells with 
both the SLP65-wt and SLP65-3XPRM2 variant, as depicted (Figure 31, A), and monitored 
the Ca2+ mobilization upon B cell stimulation (Figure 31, B).  The 3XPRM2 variant of 
SLP65 showed a significantly reduced Ca2+ signaling capacity compared to SLP65-wt even 
though the histograms (Figure 31, B-C) and the western blot analyses (Figure 34, F) point 
toward a slightly higher expression level of this protein in the cells compared to SLP65-wt. 
The difference in Ca2+ flux levels is notably more prominent at lower stimulating antigen 
concentrations (Figure 31, C). Additionally, the fluorescent speckles in the resting cells are 
much more prominent for SLP65-wt which in turn get strongly recruited to the plasma 
membrane upon BCR-mediated stimulation of the cells. This is in stark contrast to the 
SLP65-3XPRM2 which is homogenously distributed in the cytosol evidently depicting a 
lack of ability to undergo multimerization induced clustering. On stimulation of the cells, 
this construct shows little to no translocation to the plasma membrane (Figure 31, E). Finally, 
I measured the extent of phosphorylation of the two SLP65 constructs upon stimulation of 
the cells over the course of 10 mins. Despite higher expression level of SLP65-3XPRM2, 
this variant shows reduced phosphorylation levels, especially at 5 mins time point and almost 
no phosphorylation after 10 mins of stimulation. I used two α-SLP65 antibody clones to 
detect the total SLP65 expression level in the respective cell populations due to their capacity 
to recognize different epitopes. The D8R3G antibody binds an epitope in the C-terminal 
domain of SLP65 and thus equally recognizes SLP65-wt and SLP65-3XPRM2 without any 
bias. However, D3P2H antibody recognizes residues around Arg282 of wild type SLP65 i.e. 
residues surrounding the PRM4 in the SLP65-wt (refer sequences mentioned in figure 31, 
A) which was now exchanged for the PRM2 in SLP65-3XPRM2 construct. The inability of 
this antibody to detect SLP65-3XPRM2 with sufficient efficiency thus served as a control 











Figure 31: Increasing the affinity of the individual PRM-SH3 domain interactions reduces the signaling 
capacity of SLP65. 





 (A) SLP65-deficient DT40 cells were transduced with citrine-tagged SLP65-wt (red line) or a variant with 
PRM3 and PRM4 exchanged for the PRM2 (blue line). Numbers 1,2,3 and 4 depict the individual PRMs with 
the respective protein sequence of each mentioned below the domain architecture of the protein. The Ca2+ 
influx in transduced citrine positive cells upon stimulation with (B) 2µg/ml or (C) 0.2µg/ml α-chicken IgM 
F(ab ́)2 was monitored by flow cytometry. Un-transduced SLP65-deficient cells served as the negative control. 
(D) The histograms indicate the expression levels of citrine-tagged wild type and 3XPRM2-variant  SLP65 
fusion proteins in the respective cell populations. (E) Intracellular localization and membrane recruitment of 
the SLP65 proteins 1min after stimulation (2µg/ml α-chicken IgM F(ab ́)2) was observed by confocal 
microscopy. (F) Cell lysates were prepared after stimulation of SLP65-wt and SLP65-3XPRM2 expressing 
DT40 cells with 2µg/ml α-chicken IgM F(ab )́2. SLP65 phosphorylation was analyzed by SDS-PAGE and 
immunoblot analyses with antibodies against phospho-SLP65 (pSLP65). Total SLP65 was detected using two 
different α-SLP65 antibody clones: D8R3G which binds an epitope in the C-terminal domain of wild type-
SLP65 and D3P2H which recognizes residues around Arg282 of wild type-SLP65.  
 
 Deletion of a 57-amino acid segment in the PRR of CIN85 does not affect the 
amplitude of Ca2+ flux in B cells 
In the previous section, the reason why the phase-separation studies were performed with 
the CIN85Δ57 construct was the difficulty in procuring large quantities of the recombinant  
 full length-CIN85 protein. This meant that, although CIN85Δ57 provided technical 
convenience, it did not represent a true physiological picture in terms of CIN85 structure. 
Therefore, as a contribution to the above-mentioned studies, and equipped with a CIN85 
knock-out cell lines, I set out to test the functional capabilities of the Δ57-variant of CIN85 
compared to its full-length counterpart.  I created a CIN85 construct lacking 57 amino acids 
in the PRR, starting at residue 369 (mimicking the construct used for phase-separation 
studies) and transduced the construct into the CIN85-deficient DG75 cells (Figure 32, A). 
Additionally, the CIN85-deficient cells, and the cells expressing CIN85-wt, CIN85-∆CC, or 
the EGFP mock served as important controls. The expression of the CIN85 variants and 
CD2AP in these cells was confirmed by immunoblot studies (Figure 32, B). Subsequently, 
I analyzed the Ca2+ flux in these cells upon BCR-mediated stimulation (Figure 32, B). The 
Ca2+ flux in the cells expressing CIN85-Δ57 and CIN85-wt was higher compared to the 
controls, with the CIN85-Δ57 variant even appearing to be better than CIN85-wt at 
conducting Ca2+ mobilization. This could however be explained by the differences in the 
expression levels of the two citrine-tagged proteins as seen in figure 32, D with the cells 
expressing CIN85-wt showcasing a rather broad range of citrine signal profile with more 
cells expressing comparatively lower levels of CIN85-wt. This helped in confirming that the 
CIN85-Δ57 that was used for performing most in vitro phase-separation studies was indeed  
 





functional in B cells and reduced the scepticism with regard to the biological function of this 
protein.  
 
         
 
 
Figure 32: CIN85 lacking a 57-amino acid fragment in its PRR can conduct Ca2+ mobilization. (A) 
CIN85-deficient DG75 cells were transduced with citrine-tagged CIN85-wt (green line) or a variant lacking 
57 amino acids starting at residue 369 (blue line) as depicted. (B) Cell lysates were prepared from DG75 cells 
either lacking CIN85 (KO), or expressing the following: wild type CIN85 (wt), ∆CC deletion mutant (∆C), 
∆57-variant of CIN85 (∆57) or EGFP mock. Expression levels of CIN85 and CD2AP were analyzed by SDS-
PAGE and the subsequent staining of the immunoblot with antibodies against the respective proteins. (C) The 
Ca2+ influx in the above-mentioned transduced citrine positive cell populations was monitored by 
flowcytometry upon stimulation with 0.5µg/ml α-human IgM F(ab ́)2. (D) The histograms depict the 








Chapter 3: Discussion 
As per the basic understanding, the activation of B cells forms an integral part of an 
individual’s capacity to mount a functional humoral response against invading pathogens, 
the hallmark of adaptive immunity. There are several factors controlling the intensity and 
the onset of this response. The chief aspects are the manner in which signals are transduced 
by the B cell antigen receptor and the subsequent processing of those signals by the 
appropriate effector systems. In my doctoral thesis, I have aimed to shed light on the 
contribution of the adaptor proteins CIN85 and CD2AP to the master regulator SLP65 in the 
process of BCR-proximal and distal signaling events.  
 
I achieved the following objectives during the course of my work: 
 
o Creation of CIN85-deficient and CIN85/CD2AP-double deficient human DG75 and 
mouse IIA1.6 sub-cell lines using the CRISPR/Cas genome engineering tool. I 
created a cellular model system that could facilitate the study of functional properties 
of these adaptor proteins in the process of BCR-mediated B cell activation.  
o It was established that CIN85 lowers the stimulation threshold for BCR-mediated B 
cell activation i.e. it predisposes B cells to respond to lower antigen concentrations.  
Additionally, this positive regulation of the SLP65-mediated Ca2+ mobilization is a 
feature for both the human DG75 and mouse IIA1.6 cells. 
o The influence of CIN85 to the process of PKCβ membrane localization was studied 
and the key observation made that the presence of CIN85 promotes PKCβ membrane 
recruitment.  
o Amphiphysin 2/BIN 1 occupies an identical interaction module with SLP65 as do 
the steady interactors CIN85 and CD2AP. It thus appears as a novel SH3-domain 
harbouring SLP65-interaction partner, that can dock onto the atypical 
proline/arginine motifs on SLP65 in the absence of the significant binding 
companions.  
o SLP65/CIN85 clusters were discerned to exist as micron sized, phase separated 
droplets, concentrated as part of the membrane-less signaling organelles, primed for 
activation upon BCR-ligation.  
 





3.1 Not all heroes wear capes: The importance of  CIN85/CD2AP adaptor proteins 
in BCR signaling 
 
While SLP65 is the master regulator for BCR-signaling, via the assembly of Ca2+ initiation 
complex, it is dependent on the constitutive interaction with CIN85/CD2AP for its function. 
This complex encompasses a functional unit as demonstrated by the mutational analyses in 
cultured B cells. The importance of CIN85-SLP65 interaction for the immune system has 
been demonstrated by studies performed on mice harbouring B cell-specific deletion of 
CIN85 (Kometani et al., 2011). The patients harbouring deletion in the CIN85 encoding gene 
showcased varying levels of defect in their serum antibody titers which further highlighted 
the significance of CIN85. The primary cells pose a limitation to the scope of genetic and 
mechanistic analyses owing to the scarcity of cellular reserve. 
 
For studying the signaling contribution of the adaptor proteins CIN85 and CD2AP and the 
mechanism of their complex formation with SLP65, it was imperative to create knock-out 
cell lines that could facilitate biochemical and mutational studies. Two cell lines, each from 
a different species were chosen, namely,  the human DG75 and the mouse IIA1.6 cell line. 
Majority of the understanding of the BCR-signaling events stem from the studies performed 
in the chicken DT40 cells due to the technical advantage of having a strong grasp over the 
genetic system; this facilitated convenient targeted genomic modifications and subsequent 
analysis of phenotypes. However, DT40 being a chicken cell line, poses a disadvantage, in 
that the observations made fail to accurately reflect the true physiological picture of the 
higher order mammalian systems. Therefore, in order to investigate and mimic the patient 
conditions as described in section 1.3.2., the creation of cellular model systems using the 
abovementioned  human and mouse B cell lines was undertaken.   
 
Physiologically the most significant role of CIN85 and CD2AP adaptor proteins was 
discerned to be their support to SLP65 in BCR-mediated Ca2+ mobilization specifically at 
low stimulating antigen concentrations. This is of utmost significance physiologically as an 
early response to low antigen levels would facilitate early clearance of the pathogen, 
significantly reducing the risk of the pathogen-caused damage to the host.   
 





A significant reduction in NF-κB pathway activation has been reported in several studies 
(Kometani et al., 2011; Oellerich et al., 2011). Similar observations could not be reported in 
the knock-out system generated in this study owing to several technical limitations. DG75 
B cell line which is a Burkitt’s lymphoma cell line exhibits a deregulated c-Myc expression 
which in addition to other genomic modifications aide the signaling pathways that are meant 
to facilitate anti-apoptotic factors like NF-kB (Nagel et al., 2014). The pathway activation 
axis does not involve signals transduced by the BCR as antigen stimulation had no effect on 
the basal levels of phosphorylated IκBα. On the other hand, IIA1.6 cells, did show 
stimulation dependent activation of this pathway. However, only mild differences, if any, 
were seen. This could be explained by the fact that more prominent defect in the serum IgM 
levels of the patients were reported, indicating a more prominent role of CIN85 in NF-kB 
activation in naïve B cells, instead of the class-switched memory B cells. IgG-BCR 
expressing B cells can transduce fortified signals due to the presence of a facilitating ITT 
motif in addition to the canonical ITAM motif, which could modulate signals transmitted 
for the NF-kB activation (Figure 33).  
 
 
Figure 33: Human DG75 cells and the mouse IIA1.6 cells represent B cells of different developmental 
stages. The main signal transduction unit for the mIgM BCRs is the ITAM signaling motif that participates in 
canonical BCR-signaling. On the contrary the IgG BCRs on the surface of IIA1.6 cells represent class switched 
cells that in addition to the conventional ITAM motif are also equipped with an ITT motif to reinforce the 
signals that are generated from the canonical ITAM signaling.  
 
However, the DG75 cells could be used to monitor the plasma membrane recruitment of an 
upstream NF-kB pathway element, PKCβ, where it was observed that the presence of CIN85 
positively regulates the plasma membrane recruitment and thus the activation of this enzyme 
(Section 2.1.2). Additionally, mice lacking B cell-specific  CIN85 expression and mice  
 





lacking PKCβ expression exhibit similar phenotypes. PKCβ deletion resulted in low IgM 
and a subtype of IgG, IgG3 levels, a disturbed B1 B cell compartment and reduced T Cell 
dependent responses (Leitges et al., 1996).   
 
In B lymphocytes, internalization of the BCRs is critical to a process called antigen 
presentation. The BCRs recognize the antigen and internalize it by endocytosis (Batista & 
Neuberger, 2000; Suzuki et al., 2009). Once internalized  these antigens are degraded into 
antigenic peptides that are loaded onto major histocompatibility complex (MHC) class II 
molecules and presented to primed T lymphocytes (Mitchison, 2004).  
 
CIN85 has commonly been implicated in the ligand-induced internalization of tyrosine 
kinases receptors by formation of a complex involving endophilins, CIN85 and Cbl (Petrelli 
et al., 2002; Soubeyran et al., 2002; Szymkiewicz et al., 2002). Deformation of the cell 
membranes and cytoskeletal remodelling is essential for cell surface receptors  (Doherty & 
McMahon, 2009; Johannes et al., 2015). Endophilins modify membrane phospholipids and 
mediate  invagination of the  plasma membrane. Via their SH3 domains, endophilins bind 
the proline rich regions of CIN85. Simultaneously, CIN85 interacts with the C-terminus of 
Cbl which has been reported in multiple sources to be involved in receptor internalization, 
with Cbl mutants inhibiting this process  (Lee et al., 1999; Levkowitz et al., 1999; Zeng et 
al., 2005; Huang et al., 2006). Stepping beyond the RTKs, it has also been established that 
ablation of Cbl impacts BCR endocytosis and the underlying cytoskeletal dynamics (Jacob 
et al., 2008). CIN85 is the cognate adaptor that interacts with Cbl and connects Cbl to the 
endocytic machinery.  
 
Upon ligand‐induced activation of EGF receptors, Cbl binds to phosphorylated receptors 
and promotes receptor ubiquitination. Cbl is also tyrosine‐phosphorylated in this complex 
leading to translocation of CIN85/endophilin in the vicinity of active EGF receptors, 
whereby endophilins together with dynamin and Amphiphysin control the clathrin‐mediated 
internalization (Dikic I., 2002) 
 
Using the CIN85/CD2AP-double deficient cells I generated, I proceeded to test if the model 
for internalization of RTKs is also applicable to the BCRs on the surface of B cells. I  
 





observed that for both human DG75 and IIA1.6 cells, the presence of CIN85 did not impact 
the cell surface-BCR internalization, indicating that in B cells, CIN85 possibly is not 
involved in the receptor internalization process. Similar reports came from studies in mice 
with B cell specific CIN85 ablation. Kometani et al., 2011, additionally, putting these results 
in context of other studies reported where BCR-downregulation is inhibited in Cbl-deficient 
B cells (Kitaura Y. et al., 2007), it can be interpreted that the normal BCR internalization 
levels in CIN85/CD2AP deficient cells is due to the fact that this process occurs in a Cbl 
dependent but a CIN85 independent manner. This could in turn possibly hold true because 
of differential signalosome participation of CIN85 where it preferentially associates with 
SLP65 rather than Cbl in BCR signaling context. My results nevertheless allow for the 
alternative possibility that CIN85 and CD2AP participate, redundantly, in BCR endocytosis. 
 
At a cellular level, a novel strategy to monitor the impact of CIN85 on cell-viability was 
undertaken in a co-culture setup where the CIN85-deficient cells and cells expressing CIN85 
were cultured together in the same dish under appropriate culture conditions. The respective 
population abundance was then monitored over time via flowcytometry. The advantage 
conferred by a co-culture system of this kind, was the possibility to simulate the B cell 
compartment of the patients’ mother. The immunodeficient patients previously mentioned, 
carry a deletion mutation in the only CIN85 gene which is located on the X chromosome, 
reportedly resulting in manifestation of the clinical symptoms. Their mother however, who 
is hemizygous for the gene deletion, with one healthy and one mutated allele of CIN85, 
exhibits no clinical symptoms. Taking into consideration the chromosome silencing as part 
of X-chromosome inactivation in females which reduces the number of actively transcribed 
X chromosomes to one per cell, and the fact that the inactive chromosome is randomly 
selected (The Lyon Hypothesis, Rédei 2008), the B cell compartment of the mother would 
consist of a heterogenous mixture of two cell populations: Cells  expressing CIN85 and the   
cells that lack CIN85 expression. The co-culture system I created aimed to replicate this 
chimeric cellular state. Such a system could give an indication as to the survival advantage, 










The human DG75 and the mouse IIA1.6 cells deficient in CIN85 expression were mixed 
with the respective citrine-tagged CIN85 expressing counterparts in a 1:1 ratio and the 
differences in the cell viability monitored over time by monitoring the abundance of non-
fluorescent and fluorescent cells via flowcytometry. The DG75 cells showed no difference 
in the rate of cell growth or viability over the time points analysed, however, for the IIA1.6 
cells, there was a slight decrease in the abundance of the CIN85-negative cells after co-
culturing. 
 
 These observations when studied in the context of clinical symptoms, paves the way to 
explore two aspects: one, the possibility that the immunodeficiency of patients correlates to 
the poor viability of B cells, resulting in shorter lifespans and a higher turnover which 
becomes especially relevant with regard to the IgG type memory B cells, represented by the 
IIA1.6 established cell line, indicative of B cell-developmental stage specific differences. 
The second aspect relates to the mixed B cell compartment of the mother/females, such that, 
over the years, due to a survival advantage conferred upon the wild-type CIN85 expressing 
B cells, this population takes over the other in making up the peripheral B cell compartment. 
Additional clarity could come from checking the mother’s peripheral B cell populations to 
check for the previously mentioned heterogeneity with regard to CIN85 expression or a 
complete overtake by a single compartment. Also, additional measurements at time points 
longer than 72 hrs, might present a more accurate indication, reflective of the true 
physiological state in terms of the viability/growth rate differences.  
 
3.2 Amphiphysin 2 (BIN 1): The hidden player? 
In the past, the interaction studies indicated that DT40 cells expressing a variant of SLP65 
incapable of interaction with CIN85 and CD2AP could not support B cell signaling. It was 
additionally observed that the NF-kB pathway activation was abrogated (Oellerich et al., 
2011). In human DG75 B cells, the deletion of SLP65 rendered the cells completely 
incapable of mounting a Ca2+ response (Schulz K., 2016).  
 
Upon simulating a similar absence of interaction, while approaching with the absence of 
CIN85 and CD2AP the results were confounding. While the presence of CIN85 significantly  
 





improves the Ca2+ signaling, it’s absence, combined with the absence of CD2AP, does not 
abrogate signaling to the same extent as in the case of SLP65-deficiency (Section 2.1.1). The 
explanation for this could be possible functional redundancies offered by additional 
signaling elements in the B cells that potentially substitute for the absence of these adaptor 
proteins, can support SLP65 function  thus enabling B cells to mount appropriate immune 
response.  
 
Having the CIN85 and CD2AP dKO cells at our disposal, it was possible to detect any 
interaction partners of SLP65 that have so far remained undetected due to the abundance of 
the more significant binding partners. An identical mass spectrometric approach as  the one 
previously used in order to establish the highly specific interaction between SLP65 and 
CIN85/CD2AP was used for identification of any additional stimulation independent 
interaction partners that could have so far been an enigma.  
 
A new molecule that could interact with SLP65 with high affinity was reported. The results 
were corroborated from both DG75 as well as the IIA1.6 cell lines from the Forward as well 
as the Reverse SILAC labeling experiments (Section 2.2). In both the cases, this protein was 
the premier candidate that could partake in interaction with SLP65 using exactly the same 
interaction modules as CIN85 and SLP65. This protein was Amphiphysin2/BIN1, part of the 
Bin1/Amphiphysin/RVS167 (BAR) family of proteins. Interestingly, the domain 
architecture of Amphiphysin 2 also revealed similarity to CIN85 and CD2AP (Figure 34).  
It has an SH3 domain on its C-terminus which possibly enabled interaction with the 
proline/arginine rich motifs of SLP65. Similar to CIN85, the human BIN1 gene also 
undergoes alternative splicing in a cell-type-specific manner (Ellis et al., 2012; Fugier et al., 
2011; Nicot et al., 2007). Additionally, CD2AP and BIN1 have displayed overlapping 
functions. Both have been shown to be involved in endocytic trafficking related processes 
(Ubelmann et al., 2017).  
 
So far, the more established function of Amphiphysin 2/Bin 1 is reported to be with regard 
to the ability to interact with Myc and conduct tumor suppressive functions in muscle cells 
(Wechsler-Reya et al., 1998). The functional confirmation of the possible participation of 
this protein in BCR-signaling is confirmed from experiments  
 





(Pirkuliyeva S., 2015) where the BAR domain when used to replace the N-terminal domain 
of SLP65 functions just as well as on replacing the SLP65 N-terminal domain with the 
coiled-coil domains of CIN85 and CD2AP (Kühn J., 2015). In these experiment, it was also 
shown that on combined actions of replacement of the N-terminal domain with the BAR 
domain and the disruption of the proline/arginine motifs in SLP65, the cells lose the capacity 
to mobilise Ca2+. (Pirkuliyeva S., 2015). This would additionally prevent any other signaling 
molecules to interact with SLP65 (including BIN1) that could provide functional support. 
Mere plasma membrane recruitment of SLP65 is not sufficient to support its function but 
multimerization mediated localised enrichment is essential for proper B cell activation. The 
would mean that merely recruiting SLP65 to the plasma membrane via its BAR domain 
would not be enough for Amphiphysin 2 to support its function entirely, there should be a 
way for it to organise SLP65 containing micro-clusters.  In this regard, reports have been 
published on the mechanism of BAR-family proteins to mediate multimerization via 
membrane binding activities with the coordination of additional domains,  thus 
accomplishing scaffolding and signaling functions (McDonald & Gould, 2016). 
Amphiphysin2/BIN1 thus harbours properties that make it the golden candidate for 





Figure 34: Domain architecture of Amphiphysin 2a or BIN1-isoform 1.  Protein domains of Amphihysin 
2a also known as the BIN1 isoform 1. N represents the N-terminal amphipathic helix which is followed by the 
BAR domain named so from the proteins Bin, Amphiphysin and Rvs. This is followed by the phosphoinositide 
binding site (represented as PI); PRR represents the proline rich region followed by the Myc-binding domain 












3.3 The Savvy Separator: Biophysical process behind SLP65-CIN85 complex 
formation 
 
This journey began with the initial evidence that the B-cell antigen receptor signals through  
a so-called preformed transducer module of SLP65 and CIN85, as has been referred to 
multiple times in my text (Oellerich et al., 2011). In our collaboration with Prof. Griesinger’s 
group we found that SLP65-CIN85 micro-clusters in fact phase separate following the oil 
droplets in water analogy, thus forming membrane-less densely packed signalosomes that 
prime SLP65 to efficiently respond to signals transduced by the BCR. Additionally, Cryo- 
EM studies hinted that this phase separation is in fact tripartite involving SLP65, CIN85 and 
vesicles (Section 2.3.1). This mechanism of organizing signaling molecules into intracellular 
compartments is rather common.  Studies in T cells indicate that phase-separated signaling 
elements proximal to the T cell antigen receptor (TCR) promote T cell activation  (Su et al., 
2016). The TCR-proximal signaling mechanisms are quite similar to the BCR signaling 
events, representing a common biological principle governing the intracellular signaling in 
these cells. This is a prudent mechanism as for enzymatically inert adaptor proteins, that 
cannot amplify signals by catalyzing biochemical reactions, a one-to-one interaction 
mediated signal transduction would be highly inefficient in physiological considerations. 
However, supramolecular assembly of multivalent proteins into signalosomes could enable 
efficient signaling with multiple proteins mediating respective functions being enriched in 
these clusters, positioned for immediate activation upon B cell stimulation (Rosen, 2014). 
Additionally, not just signal promoting but signal inhibiting elements could further fine tune 
signal transduction in cells (Strzyz, 2019).  
 
Mutational analyses aided in investigating the factors that could either contribute to an 
increase in the micro-cluster forming capacity or factors that could negatively influence 
clustering events. I observed that due its ability to form stable coiled-coil trimers, the C-
terminal domain of CIN85 is crucial for multimerizing SLP65. Disrupting all the CIN85 
interaction sites and replacing the N-terminal domain of SLP65 with just the coiled-coil  
domain of CIN85 is enough for supporting wild type levels of Ca2+ signaling. In terms of 
quantitative considerations, a CIN85 coiled-coil domain-mediated oligomerization of a  
 





SLP65 molecules which is incapable of interacting with additional CIN85 molecules is 
sufficient to support phase-separation and Ca2+ signaling in B cells. Due to SLP65-N 
terminus representing the membrane binding moiety for vesicle recruitment, these results 
indicated that the coiled-coil domain of CIN85 has the capacity to somehow support vesicle 
interaction to support tripartite phase separation. Indications of the ability of CIN85 coiled-
coil domain to bind to membrane lipids have been reported (Kühn et al., 2016). 
Expressing a variant of CIN85 incapable of forming stable trimers (L619K) reduced Ca2+ 
mobilization capacity emphasizing the essential step of efficient organization of SLP65 into 
signaling competent micro-clusters. 
 
 
 A “super-interactor” variant of SLP65: SLP65-3XPRM2 that interacted with CIN85 with 
supposedly increased affinity showed unexpected results of reduced Ca2+ signaling. It 
additionally showed reduced levels of phase-separation in in vitro studies (results not 
showed). This could be explained on takins the stoichiometry of interacting molecules into 
consideration. A stronger affinity-based interaction would result in one SLP65 molecule 
being allowed to interact with one CIN85 molecule in a rigid one-on-one interaction 
preventing the otherwise dynamic binding, involving interplay of several SLP65 and CIN85 
molecules necessary for the formation of the multimolecular signaling complexes.  
It would be of interest to corroborate these results by testing if a similar effect is rendered 
from the side of CIN85, where multiple dominant affinity SH3 domains mediate interactions 
with SLP65. Therefore, the qualitative and quantitative aspects of droplet formation hold 
much interest as well as the ways in which their assembly is regulated. Stepping away from 
its interaction with SLP65, it is reasonable to assume that CIN85 undertakes similar droplet 
formations enriching signaling elements that participate in other downstream signaling 
pathways, creating separate effector systems the composition and biophysical properties of 












To encapsulate, the results of my PhD study shed light on the involvement of CIN85 and  
CD2AP adaptor proteins in BCR-mediated signaling events. CIN85-facilitates SLP65 
multimerization. More specifically, the C-terminal coiled-coil domain which forms stable 
CIN85-trimers mediates this action, and the prevention of this step, hampers B cell 
activation, especially when the simulating antigen concentrations are low. CIN85 
demonstrates cell-type specific functions. While in most cell types it is involved in ligand 
induced  internalization of receptor, in B cells, CIN85 seems to  have an exclusive role of 
scaffolding effector molecules downstream of the BCR, increasing their local 
concentrations. It is subject to functional redundancy presented by CD2AP and in the 
absence of both the adaptor proteins, a new player might step into the picture in the cells 




Chapter 4: Methods and Materials 
4.1 Materials  
 Technical devices 
Device Manufacturer 
Agarose gel electrophoresis system Peqlab 
Amaxa Nucleofector TM Lonza 
Amnis ImageStream®X MarkII Imaging Merck 
Cell culture incubator heracell®  Heraeus 
Confocal laser scanning microscope tcs sp2  Leica microsystems 
Countess TM cell counter Invitrogen 
Electrophoresis power supply eps 301 Amersham biosciences 
Electrophoresis system Hoefer se600 Amersham 
Freezer platilab 340 Angelantoni industrie 
Ice machine Ziegra 
Incubation shaker unitron  Infors 
Incubator kelvitron® t  Heraeus  
Laminar flow cabinet hera safe  Heraeus  
Light microscope telaval 31  Zeiss 
LSR II Becton Dickinson 
Magnetic stirrer m21/1 Framo Gerätetechnik 
Mastercycler epgradient Eppendorf 
  





Mini protean tetra cell Bio-rad laboratories 
Nanodrop 2000  
Neubauer improved counting chamber 




Rocking shaker  Neolab  
Thermomixer comfort  Eppendorf 
ChemoCam Imager Intas 
Vortex Genie 2 Scientific Industries 
Water Bath Schütt Labortechnik 
Water Purification System Milli-Q Sartorious 
Table 2: Technical devices used in this study 
 
  Software and Databases 





Visualise protein and DNA 
sequences, plasmid mapping and 
primer designing 
FlowJo 7.6.5 TreeStar Flowcytometry data analysis 
FACSDiva BD Biosciences Flowcytometry data acquirement 
ImageJ W.Rasband; NIH  Image processing 
Perseus 1.5.5.0 Cox and Mann, 2008 Interpreting protein quantification 
and interaction data 
GraphPad Prism GraphPad Software Inc. Data analysis and graphing 




Chemostar professional  Intas  Western blot data acquirement 
Leica confocal software Leica Microscopy data acquirement 






Benchling Sajith, Ashutosh Singhal 
and Cory Li; MIT 
DNA and protein sequence 
analysis and editing 
NCBI database NCBI Genomic and proteomic data 
analysis 
Ensembl EMBI-EBI Genome browsing 
Uniprot Uniprot Consortium Protein information 
Table 3: Software and databases 
 
 Other digital and online tools 
Name Application 
http://tools.genome-engineering.org Designing CRISPR guide sequences 
http://multalin.toulouse.inra.fr/multalin/ Sequence alignment 
http://bioinfo.ut.ee/primer3-0.4.0/ Primer selection 
Table 4: Digital tools used in this study 
 
  Additional materials and their supplier  
Material Supplier 
6X DNA loading dye  Thermo Fischer Scientific  
5X Phusion HF Buffer New Englands Biolabs  
10X NEBuffers Cutsmart bufers  New England Biolabs  




Cell culture material  Greiner, Sarstedt, Nunc  
GeneRulerTM 1 kb DNA ladder   Thermo Fischer Scientific  
Indo-1 AM  Invitrogen  
Nitrocellulose filter Hybond ECLTM   GE Healthcare  
Whatman Gel Blotting Paper  GE Healthcare  
Puromycin  InvivoGen  
Polybrene   Sigma  
NP-40 (IGEPAL CA-630)  Sigma-Aldrich  
NuPAGE LDS sample buffer (4X)  Invitrogen   
NuPAGE sample reducing buffer  
(10X)  
Invitrogen  
Prestained broad range protein marker (11-
190 kDa)   
New England Biolabs  
RPMI 1640 + Glutamax  Gibco  
SILAC RPMI 1640 Medium  Thermo Scientific  
Streptavidin-Sepharose beads  GE Healthcare  
Streptavidin APC  BD Biosciences  
TransIT™  293 Transfection Reagent  Mirus  
Table 5: Consumables 
 
 Antibodies 
For western blotting purposes, the primary antibodies were used at a 1:1000 dilution 
and secondary antibodies were used at a 1:10000 dilution. For cell surface BCR staining, 
fluorophore labelled antibodies were used at a 1:100 dilution for the flowcytometric analysis. 
Stimulating F(ab’)2 concentrations for B-cell stimulation are mentioned in the respective 
figure legends.  





Target, host species Manufacturer (Cat. no. ) 
Primary antibodies 
α-CIN85 (D1A4), Rabbit monoclonal Ab CST (12304) 
α-CD2AP, Sheep polyclonal Ab Novus Biologicals (AF4474) 
α-pSLP65 (Y96). Rabbit polyclonal Ab  CST (3601) 
α-SLP65 (D3P2H), Rabbit monoclonal Ab CST (36438) 
α-SLP65 (D8R3G), Rabbit monoclonal Ab CST (12168) 
α-pIκBα (Ser32) (14D4), Rabbit monoclonal   Ab CST (2859) 
α-IκBα,, Rabbit polyclonal Ab  CST (4814) 
α-β-Actin (8H10D10), Mouse monoclonal Ab  CST (3700) 
Secondary Antibodies 
α-mouse IgG2a-HRP  Southern Biotech (1081-05) 
α-mouse IgG2b-HRP  Southern Biotech (1091-05) 
α-rabbit IgG-HRP  Southern Biotech (4030-05) 
α-goat IgG-HRP  Southern Biotech (6160-05)  
α-sheep IgG-HRP Southern Biotech (6150-05) 
Antibodies for FACS 
Biotin tagged α-mouse IgG Southern Biotech (1030-08) 
Biotin tagged α-human IgM Southern Biotech (2020-08) 
α-Human IgM-APC, mouse IgG1 Southern Biotech (902011) 
α-Mouse IgG2a-CY5, mouse IgG1, goat Southern Biotech (108015) 
Antibodies used for B cell stimulation  
Goat α-Human IgM F(ab')2  Jackson ImmunoResearch 
(109-006-129) 




Goat α-Mouse IgM F(ab')2  Jackson ImmunoResearch 
(115-006-020)  
Mouse α-Chicken IgM F(ab')2  (M4) Biozol (8310-01) 
Table 6: Antibodies used for western analysis 
 
 Vectors and constructs  
Vector backbone Insert Source 
Vectors used for cloning 
pCR2.1  - Invitrogen 
pCR2.1 CIN85CCdNSLP652,3  Julius Kühn 
pCitN1 - Michael Engelke 
pMSCVpuro - BD Biosciences        
Clontech   
pMSCVpuro Citrine Sona Pirkuliyeva 
pMSCVpuro NCitCIN85  Vanessa Bremes 
Vectors used for retroviral transduction and exogenous expression of proteins 
pMSCVpuro  EGFP  Christoffer Hitzing  
pMSCVpuro  NCitCIN85  Vanessa Bremes  
pMSCVpuro NCitCIN85d57 This study 
pMSCVpuro  NCitCIN85 ΔCC  Vanessa Bremes  
pMSCVpuro NCitCIN85Q541E  This study 
pMSCVpuro NCitCIN85T266I  This study 
pMSCVpuro NCitCIN85R413Q  This study 
pMSCVpuro NCitCIN85L619K  This study 
pMSCVpuro  NCitCD2AP Vanessa Bremes  




pMSCVpuro CCitSLP65 Vanessa Bremes 
pMSCVpuro CCitdNSLP65M2,3 Julius Kühn 
pMSCVpuro CCitdNSLP65M1,2,3,4 This study 
pMSCVpuro PKCβII Kathrin Schulz  
 
Table 7: Vectors and expression constructs used in this study 
 
 Primers and oligonucleotides  
Primer name  Primer sequence 5’ – 3’  
M13 Fwd   TGTAAAACGACGGCCAGT  
M13 Rev   CAGGAAACAGCTATGACC  
pMSCV Fwd  CCCTTGAACCTCCTCGTTCGACC  
pMSCV Rev  GAGACGTGCTACTTCCATTTGTC  
EGFP-C Fwd GTCCTGCTGGAGTTCGTG 
CMV Fwd CGCAAATGGGCGGTAGGCGTG 
CCdNSLPM2,3 Fwd TAAGCAAGATCTATGGAAGGAAAACCAAAG             
ATG 




SLP653XPRM2NotI Rev GCGGCCGCTTATGAAACTTTAACTGCATA 
CIN85d57 Fwd TAAGCAGGATCCGGTGGAGGCCATAGTGGAGTTT 
CIN85d57 Rev TGCTTAGCGGCCGCTCATTTTGATTGTAGAGCTTT 
CIN85Q541E Fwd CTGTTACCATATCCGAAGTGTCTGACAACA 
CIN85Q541E Rev TGTTGTCAGACACTTCGGATATGGTAACAG 




CIN85T266I Fwd AAATGGACAGCAGGATAAAGAGCAAGGATT 
CIN85T266I Rev AATCCTTGCTCTTTATCCTGCTGTCCATTT 
CIN85R413Q Fwd CCAATTCTCTCAGCCAACCTGGCGCACTGC 
CIN85R413Q Rev GCAGTGCGCCAGGTTGGCTGAGAGAATTGG 
CIN85 L619K Fwd ACACAGGTCCGCGAGAAGAGGAGCATCATCGAGAC 




NCitCIN85FLNot1   
Rev 
TGCTTAGCGGCCGCTCATTTTGATTGTAGAGCTTT 
mCIN85 Ex3 Fwd CTCAGTCGTTCTCCTGATGCTCA 
mCIN85 Ex3 Rev CATACAAGGGTTTTCAAATGTGCC 
hCIN85 Ex3 Fwd CCATAGTTACATAAGGTCGCCTCAC 
hCIN85 Ex3 Rev CAGGGAGGGAACCTCTTTTTCC 
mCD2AP Ex2 Fwd TGAGCCGGTGCACAGAAG 
mCD2AP Ex2 Rev CCATAAGTGCTGATTCGCTGT 
hCD2AP Ex2 Fwd TGCCTCGGCCTCCCAAAGTGCTGGG 
hCD2AP Ex2 Rev  CACTTAACCTCTCAATCTAAATATC 
mCIN85-CRISPR  
guide oligo Fwd 
CACCGCCACTGGATACATCGTGCAT 
mCIN85-CRISPR  
guide oligo Rev 
AAACATGCACGATGTATCCAGTGGC 
hCIN85-CRISPR  
guide oligo Fwd 
CACCGTCCACTGGGCACTTCGTGCA 
hCIN85-CRISPR  
guide oligo Rev 
AAACTGCACGAAGTGCCCAGTGGAC        











Table 8: Primers used in this study (Fwd for Forward, Rev for reverse) 
 
 Chemical reagents  
The chemicals and reagents used in this study were supplied by Invitrogen, Merck, 
Carl Roth, or Sigma unless mentioned otherwise.  
 Buffers and Solutions used in this study 
Buffer/Solution Composition 
TAG lysis buffer 10 mM Tris pH 8.0, 50 mM KCl, 0.45% 
NP-40, 0.45% tween-20, add dH2O  
Tris acetate EDTA (1X TAE)  40 mM Tris-acetate pH8.0, 10 mM NaOAc,  
1 mM EDTA, add. ddH2O  
B cell lysis buffer  
  
137.5 mM NaCl, 50 mM Tris pH 7.8, 1 mM  
Na3VO4, 0.5 mM EDTA pH 8.0, 10%  
 glycerol, 1X protease inhibitor cocktail, 1%  
NP-40 detergent, add. ddH2O  
Phosphate buffer saline (1X PBS)  137 mM NaCl, 27 mM KCl, 8.6 mM 
Na2HPO4.12H2O, 1.4 mM KH2PO4 , add.  
ddH2O  
Krebs ringer solution (1X)  140 mM NaCl, 4 mM KCl, 10 mM 
Dglucose, 10 mM HEPES pH 7.4, 1 mM  
CaCl2  




10% Resolving gel for SDS-PAGE  
  
375 mM Tris pH 8.8, 0.1% SDS, 10%  
Acrylamide and bisacrylamide, 0.00065%  
APS, 0.001% TEMED, add. ddH2O  
5% Stacking gel for SDS-PAGE  125 mM Tris pH6.8, 0.1% SDS, 5%  
Acrylamide and bisacrylamide, 0.001%  
APS, 0.001% TEMED, add. ddH2O  
SDS-PAGE running buffer (1X)  25 mM Tris, 192 mM glycine, 0.1% (w/v)  
SDS, add ddH2O  
Blotting buffer (1X)  39 mM Glycine, 48 mM Tris, 0.0375% 
(w/v) SDS, 0.01% (w/v) NaN3, 20% (v/v) 
methanol, add. ddH2O  
Blocking solution  5% BSA, 0.01% NaN3, add. 1X TBS-T  
Tris buffer saline with tween (1X TBS-T)  20 mM Tris pH 7.6, 137 mM NaCl, 0.1% 
tween-20, add. ddH2O  
2X Laemlli buffer  62.5 mM TrisHCL pH 6.8, 2% SDS, 20% 
glycerol, 5% β-mercaptoethanol, 0.025% 
bromophenolblue, add. ddH2O  
ECL solution A  200 ml 0.1 M Tris pH 8.6, 50 mg luminol   
ECL solution B   50 ml DMSO, 55 mg para-
hydroxycoumaric acid  
Table 9: Buffers and solutions used in this study 
 
 Enzymes and their suppliers 
Enzymes Supplier 
All the restriction endonucleases New England Biolabs 
Calf intestinal phosphatase New England Biolabs 
Phusion® DNA polymerase New England Biolabs 




Taq DNA polymerase New England Biolabs 
Proteinase K Macherey-Nagel 
T4 DNA ligase  New England Biolabs 
Table 10: Enzymes used in this study 
 
 Synthetic peptides 
• Central PXXXPR motif of human SLP65 – Test peptide 
Biotin – KSPPPAAPSPLPRAGKKPT 
• Binding incompetent version – Control peptide 
Biotin – KSPPPAAPSALPAAGKKPT 
Preparation: A 1 mM stock solution of the peptides was prepared in 1X sterile PBS. A part 
of the stock solution was aliquot for use and the remaining stored away at -20° C.  
Bought from:  Thermo Fischer Scientific.  
 Bacterial Strains 
One Shot Top10F’ chemically competent E. coli (Invitrogen) were used for primary cultures 
for plasmid isolation. The E. coli were grown in lysogeny broth (LB) medium constituting 
10 g/l tryptone, 5 g/l yeast extract, 5 g/l NaCl (pH7). Before inoculating the bacteria, the LB 
medium was autoclaved for 30 min at 121°C, 1.25 bar. Agar plates were prepared by adding 
2% agar-agar to the LB medium. For bacterial antibiotic selection, 100µg/ml ampicillin or 
50µg/ml kanamycin was used.   
 
 Cell lines used in this study  
DG75 (DSMZ: ACC 83)  
Human Burkitt lymphoma B cell line was established from the pleural effusion of a 10 year-
old boy with Burkitt’s lymphoma in 1975. This cell line shows suspension-cell properties in 




culture and expresses IgM-BCRs on the cell surface (Ben-bassats et al., 1977). Following 
are the sub-cell lines established from these cells: 
o DG75 cells deficient in CIN85 expression, referred to as DG75 CIN85-KO 
in this study 
o DG75 cells with a combined deficiency of CIN85 and CD2AP expression 
referred to as DG75 CIN85/CD2AP-dKO in this study.  
 
IIA1.6 (CVCL: 0J27) 
IIA1.6 is a mouse reticulum cell sarcoma-cell line. It is a FcγR-negative descendant of the 
more prevalent mouse B cell line called A20 (Donnou et al., 2012). These cells express cell 
surface IgG-BCRs and exhibit a semi-adherent nature in culture. Following are the sub-cell 
lines established from these cells: 
o IIA1.6 cells deficient in CIN85 expression, referred to as IIA1.6 CIN85-KO 
in this study 
o IIA1.6 cells with a combined deficiency of CIN85 and CD2AP expression 
referred to as IIA1.6 CIN85/CD2AP-dKO in this study.  
 
DT40 (ATCC: CRL-2111) 
DT40 is an avian leukosis virus (ALV) induced bursal lymphoma cell line derived from a 
Hyline SC chicken (Baba & Humphries, 1984). This cell line has suspension culture 
properties and expresses cell surface IgM-BCRs. It shows a high ratio of targeted to random 
DNA integration, thus allowing for convenient genome alterations. 
 
4.2 Methods 
 Molecular Biology based methods  
If not stated otherwise standard molecular biology methods were performed as 
recommended by the manufacturer’s  protocol  or  as  described  in  “Molecular  Cloning:  
A  Laboratory  Manual”  (Sambrook & Russell, 2001). 
 





4.2.1.1 Isolation of genomic DNA 
Genomic DNA extraction from the established B cell lines was performed by harvesting 
1x106 cells, washing once with 1XPBS, and finally lysing the cells in 100 μl TAG-lysis 
buffer containing 1 μl proteinase K (20 mg/ml). Temperature conditions: 56°C for 3 hrs. 
Subsequent heat inactivation of the enzyme: 95°C for 15 min. Samples were either directly 
used for polymerase chain reaction (PCR) or stored at 4°C until further use. 
 
4.2.1.2 Polymerase chain reaction 
Standard PCR protocol  
Each PCR sample was prepared according to the instructions given below. The PCR 
products were then used to perform agarose gel electrophoresis and purification procedure 
to extract DNA sample from the gel is described further below.  
  
PCR sample 
Component Amount   
ddH2O  15.07 µl  
5X Phusion buffer  5 µl  
10 mM dNTPs  1 µl  
100 ng/µl Template DNA  1 µl  
10 µM Primer Fwd  1 µl  
10 µM Primer Rev  1 µl  
DMSO 0.63 µl 
Phusion polymerase 0.3 µl 
Total  25 µl  
 
PCR Program: 
Step    Temperature   Time 
Initial denaturation  98°C     5 min 
35 cycles 
(Table continued on the next page) 
 
 





Denaturation   98°C     30 sec 
Annealing   x °C (*)    10 sec 
Elongation   72°C     30 sec/kb plasmid 
Final Elongation  72°C     10 Min 
Stop    11°C     ∞ 
* Annealing temperature = Tm primer – 3-5°C 
 
Site directed mutagenesis protocol  
For introducing specific point mutations in DNA sequence, amplification of plasmid was 
performed using complementary primers encompassing the desired mutation. The master 
mix prepared according to the instructions give below was split into two 50 µl reactions for 
PCR. One containing 1 µl Pfu polymerase and the other without any Pfu polymerase served 
as negative control.  
 
Master mix   
Component Amount  
ddH2O  82 µl  
10X Pfu Buffer  10 µl  
10 mM dNTPs  2 µl  
100 ng/µl Template DNA  2 µl  
10 µM Primer Fwd  2 µl  
10 µM Primer Rev  2 µl  
Total  
  
100 µl  
 
PCR Program: 
Step    Temperature   Time 
Initial denaturation  94°C     2 min 
35 cycles 
 
Denaturation   94°C     30 sec 
Annealing   55°C     1 min 
Elongation   68°C     2min/kb plasmid 
(Table continued on the next page) 





Final Elongation  68°C     10 Min 
Stop    4°C     ∞ 
 
The reactions were divided into two parts of 25 µl each. One was directly loaded onto the 
agarose gel for visualization and the other was treated with 1 µl DpnI to digest the template 
plasmid at 37 °C for 1 hour. The template plasmid being methylated gets removed and the 
PCR products remain intact. The sample was then used to transform competent bacteria, 
followed by plasmid purification and sequence validation.  
 
4.2.1.3 Enzymatic digestion of DNA 
1µg of DNA was incubated with 0.5-1µl of the appropriate restriction endonuclease and the 
respective NEBuffer in a total volume of 25 µl, made up with ddH2O at either the conditions 
and duration specified by the manufacturer or at 37 °C, O/N. For cloning purposes, 1 µl of 
CIP was added on top in the same restriction sample and the sample was incubated further 
for 1 hr. This prevented re-ligation of the vector. Samples could then be mixed with the DNA 
loading dye and run on the agarose gel for visualization.  
 
4.2.1.4 Agarose gel electrophoresis 
The restriction fragments or the PCR amplicons were separated based on size using agarose 
gel electrophoresis making use of agarose gels that were in the range of 1-2% agarose 
composition. The gels contained 0.1 % (v/v) Ethidium Bromide and were run in 1X TAE 
running buffer. Prior to loading on the gel, the DNA samples were mixed with 1X DNA 
loading dye. Additionally, 10 µl of 1 kb DNA ladder was loaded onto the gel. Electrophoresis 
was performed at 1.2 V/cm2 and the resolved DNA bands were viewed under the UV light. 
The appropriate bands were excised from the gel and the DNA purified using the 










4.2.1.5 DNA ligation 
Ligation of DNA fragments for cloning purposes was performed using the vector and insert 
amounts suggested by the NEBioCalculator, considering the vector and insert DNA lengths. 
1 µl of T4 DNA enzyme and 1 µl of 10X T4 ligase buffer was added to the ligation mixture 
and the final volume was adjusted to 10 µl with ddH2O. The sample was incubated at RT for 
3 hrs or at 14 °C O/N. All the ligation mixture was used for transformation of the competent 
bacterial cells, which were then plated on the LB agar plates containing appropriate 
antibiotic.  
4.2.1.6 Transformation of chemically competent bacteria 
An aliquot of competent TOP10F’ bacteria was thawed on ice, 50 ng of plasmid DNA added 
and the cells incubated on ice for about 20 min. The bacterial cells were then subjected to a 
heat-shock at 42°C for 90 sec, after which the cells were instantly placed on ice again for 2 
min. After 2 min, 500 µl of RT antibiotic free LB-medium was added to the cells for recovery 
and incubated at 37° C for about 1 hr with constant shaking. The cells were then pelleted by 
centrifugation at 16,000 g for 1 min and the supernatant discarded. The pellet was 
resuspended in 100 µl of RT antibiotic free LB-medium and the cells were then directly 
plated onto a LB-agar plate with the correct antibiotic and incubated O/N at 37 °C for 
colonies to grow.  
 
4.2.1.7 Isolation of plasmid DNA 
4 ml of LB-Ampicillin/Kanamycin was inoculated with a transformed bacterial colony and 
grown at 37 °C, at about 180 rpm speed of agitation for aeration, O/N. The next morning, 
the cultures were used for plasmid purification using the kit: Invisorb® spin plasmid mini 
two (Invitek) as per the manufacturer’s instructions. The DNA was finally eluted in 40 µl 
ddH2O. 
 
4.2.1.8 DNA sequencing 








services provided by the Microsynth Seqlab (Sequence Laboratories in Göttingen). Samples 
were prepared by combining 700 ng – 1.2 µg DNA, 30 picomol appropriate primer and 
ddH2O to a final volume of 15 µl.  
 
4.2.1.9 CRISPR/Cas9 Genome editing  
The CRISPR/Cas-based gene editing was performed according to the instructions given in 
Cong & Zhang, 2014. pSpCas9(BB)-2A-GFP vector was used for gene targeting providing 
the advantage of encoding several elements like GFP (to aid sorting of transfected cells), the 
guide sequence, as well as the Cas9 coding sequence, all in one construct. The guide 
sequences for gene targeting were designed using the online tool -  http://tools.genome-
engineering.org. Guide sequences with a high score were selected, indicating fewer off-
target effects. Additionally, the guides were selected such that, the Cas9 cleavage site 
overlapped with the binding site of a restriction endonuclease.   
 
 Cell Biology  
Cells were cultured at 37° C temperature, 5% CO2, in humidified conditions in the culture 
media listed below.  
 










packaging cell line) 
RPMI-1640 (+GlutaMax) medium, supplemented with 10% 
FCS, Penicillin/Streptomycin and 1% chicken serum. 
RPMI-1640 (+GlutaMax) medium, supplemented with 10% 
FCS, Penicillin/Streptomycin, 1mM Sodium Pyruvate, 50mM 
β-mercaptoethanol 
RPMI-1640 (+GlutaMax) medium, supplied with 10% FCS, 
Penicillin/Streptomycin, 1mM Sodium Pyruvate, 50mM β-
mercaptoethanol 
DMEM supplemented with 10 % FCS and 
Penicillin/Streptomycin.  
Table 11: Cell line specific cell culture media composition 
 





For isotopic labeling of amino acids in the cells, for mass spectrometry-based experiments, 
the cells were cultured in the appropriate medium from below:  
Heavy SILAC medium 
SILAC RPMI-1640 Medium containing 10% dialyzed FCS, 1% penicillin/streptomycin, 
0.115 mM  13C615N4 L-arginine (+10), and 0.27 mM 13C615N2 L-lysine (+8).  
Light SILAC medium 
SILAC RPMI-1640 Medium containing 10% dialyzed FCS, 1% penicillin/streptomycin and 
the corresponding non-labelled amino acids (Sigma). 
 
For the DG75 and IIA1.6 cells, the incorporation of the labelled amino acids was performed 
according to Oellerich et al., 2009. To ensure complete labeling, the cells were cultured in 
the respective medium for at least 7 days. 
4.2.2.1 Freezing and thawing of eukaryotic cells  
For freezing the cells, about 8-10 million cells were harvested by centrifugation at 300 g, 5 
min, RT. The supernatant was discarded and the pellet was resuspended in 2 ml freezing 
medium (FCS + 10% DMSO). The resuspended cells were transferred into cryo-vials, 1 ml 
volume in each and short-term storage of cells was done at -80 °C while the long-term 
storage was done at -140 °C. For thawing the frozen cells, the cryo-vials were heated in the 
37 °C water-bath. Subsequently, the thawed contents were added to 10 ml cell culture 
medium in a 15 ml falcon tube. The DMSO was removed by centrifuging the cells at 300 g, 
4 min and the supernatant discarded and the cell pellet resuspended in fresh 10 ml culture 
medium and seeded onto a 10 cm dish. The culture was allowed to grow to a confluence of 
about 50-70 %  (depending on the cell line) before further use.   
 
4.2.2.2 Amaxa Nucleofection 
For transient transfection of DG75 and IIA1.6 cell lines with the respective CRISPR/Cas 
constructs, the Amaxa® Cell Line Nucleofector® Kit V was used following the 
manufacturer’s instructions.  
 
 





4.2.2.3 Retroviral transduction of cells 
The Plat-E packaging cell line was used to produce ecotropic viral particles carrying the 
DNA to be transfected into the cells. These viral particles could only infect the mouse cells 
(IIA1.6 cells), however, when pseudo-typed with the vesicular stomatitis virus surface 
protein (VSV-G) they could infect cells of species that do not carry the ecotropic vector, 
like, the humans (DG75 cells). On infecting the target cells these viruses deliver the genetic 
material of interest.  
The adherent Plat-E cells were cultured to about 60-80% confluence on a 6 cm dish. The 
culture medium was carefully aspirated from the dish and replaced with the transfection 
solution. The transfection solution consisted of 250 µl RPMI with no FCS (pre-warmed to 
37 °C), 8 µl Trans-IT transfection reagent, about 4µg of plasmid DNA and if required 0.5 
µg of pCMV-VSV-G. Before drop-wise pouring on the cells, the transfection solution was 
incubated at room temperature for about 35 min. The next day, culture was topped up with 
1.5 ml fresh target cell medium and the cells were continued to grow under the appropriate 
culture conditions. For infecting the target cells, the supernatant was carefully collected from 
the pelleted Plat-E cells (centrifugation at 300g for 4 min) and carefully decanted over a 2ml 
culture of 1 million cells. Additionally, 3 µg/ml Polybrene solution was added to culture dish 
and mixed carefully, subjecting minimal mechanical stress to the cells. The next day, the 
polybrene containing medium was removed from the culture by centrifuging the cells and 
discarding the supernatant. The cells were re-plated and depending on the cell density, 
antibiotic selection was started with 2 µg/ml puromycin. In case of heterogenous cell 
population due to incomplete selection, the cells were additionally sorted via fluorescent 
activated cell sorting (FACS).  
 
4.2.2.4 Cell sorting 
Cells were sorted using the Fluorescence associated cell sorter (FACS), at the Cell Sorting 
Facility of the Universal Medical centre, Göttingen with the aid of Sabrina Becker. 
Approximately 6 million cells were washed once with 500 µl 1X PBS. Sorted cells were 
collected in the appropriate culture medium (R10), pelleted and then resuspended again in 
200 µl of fresh medium and finally plated in a well of the 96-well round bottom plate. The  
 





cells were cultured and expanded under the appropriate culture conditions. 
 Biochemistry  
4.2.3.1 Preparation of cell lysates 
B cells at a density of 0.5-1 million cells/ml in a culture dish were harvested by centrifugation 
at 300 g, RT for 4 min. The cell pellet was then resuspended in an appropriate volume of 1X 
PBS and the cells were counted either manually with the hemocytometer or using an 
automated cell counter countess. The cells were then harvested from appropriate volume of 
cell suspension, resuspended in medium containing no FCS (R0) and starved for 30 min at 
37 °C with sporadic mixing. The cells were pelleted again and resuspended in 200 µl R0 per 
5 million cells and stimulated with the appropriate anti-BCR antibody for the specified time 
points or left untreated for unstimulated samples. The cells were centrifuged again at 300 g, 
4 °C, for 4 min and the media aspirated carefully. The cells were lysed in 20 µl lysis buffer 
(containing 1% NP40 detergent) per 1 million cells on ice for 20 min and the cell debri was 
pelleted by centrifugation at 20000 g , 4 °C for 20 min. The supernatant comprised the cell 
lysate and was mixed with 1X laemlli buffer, boiled at 95 °C for 5 min finally loaded on the 
SDS-PAGE gel for western blotting analyses. The left-over sample could be stored at -20 
°C.  
 
4.2.3.2 Affinity purification for mass spectrometric analyses 
The cells that were grown in the Heavy or the Light SILAC medium (the composition 
mentioned in section 4.2.2) for at least a week were harvested by centrifugation at 300 g, 4 
min, RT. The cell pellet was then resuspended in 1X PBS and cell-counting was done. 
Appropriate volume of the cell suspension was centrifuged to pellet about 30 million cells 
which were lysed in 600 µl lysis buffer for about 30 min. The cell debris were pelleted by 
centrifugation at 20000 g, for 20 min, 4 °C, and the cell lysates were mixed with 1 µM final 
concentration of the biotinylated peptides. In the forward SILAC labeling, the heavy amino 
acid labelled cells were treated with 1 µM of test peptide whereas the light amino acid 
labelled cells were treated with the control peptides. In the reverse SILAC labeling, this  
 





treatment was reversed with heavy labelled cells treated with the control peptides and light 
labelled cells treated with the test peptides. Additionally, 200 µl streptavidin beads were 
added and the samples were incubated O/N on a rotating tube mixer at 4 °C. The beads were 
then washed thrice with lysis buffer at 500 g, 4 min, 4 °C. In the end, the heavy and the light 
labelled cells were combined and mixed with 120 µl of 1X LDS boiling buffer, prepared 
from 10X NuPAGE sample reducing buffer and 4X NuPAGE LDS sample buffer in ddH2O. 
The samples were then boiled at 95 °C for 5 min and sent for mass spectrometry analysis to 
the Proteomics Core Facility at the University Medical Center Goettingen. At the mass spec. 
facility, the samples were subjected to SDS-PAGE and the gel bands were treated and 
analysed via tandem mass spectrometry (MS/MS). The data was processed using the Perseus 
software, the significance requirements taken into consideration and scatter-plots 
generated. The proteins that had a H/L normalized ratio of more than 2.0 in the case of 
forward labeling experiment and less than 2.0 in the case of reverse labeling experiment 
were considered to be the relevant binding partners of the test peptides.  
4.2.3.3 SDS-PAGE 
SDS-PAGE was employed for size-based separation of proteins. 10% polyacrylamide 
resolving gel and 5% polyacrylamide stacking gel were used. The gels were cast and run in 
1X SDS running buffer. Before loading onto the gel, the samples were boiled in laemlli 
buffer at 95 °C for 5 min. The mini gel BioRad system was used to run the gels at the current 
and voltage settings of 15 mA, 250 V for the separating gel and 20 mA, 250 V for the 
resolving gel. 
 
4.2.3.4 Immunoblot / western blot analysis 
The proteins separated via SDS-PAGE were observed by immunoblotting and ECL-based 
detection. The equipment assembly consisted of the anode of the blotting chamber at the 
bottom, this was followed by two layers of whatman paper over it, a nitrocellulose 
membrane, the gel, and two more layers of whatman paper finally on top. It is important to 
note that all the layers were pre-soaked in blotting buffer. The bubbles impeding the transfer 
were removed from between the layers with the rolling motions of a pipette over the 
assembled layers. Finally, the cathode was placed on the top of the layers and protein transfer  
 





was carried out at 16 V, 240 mA for 50 min. After the completion of blotting process, the 
membrane was blocked at room temperature for 60 min with blocking solution. The 
membrane was then used for incubation with the primary antibody O/N. The next day, the 
membrane was washed three times,  5 min each,  incubated with Horse radish peroxidase 
(HRP) conjugated-secondary antibody for 60 min and washed three times again, for 10 min 
each followed by ECL-mediated detection. The ECL solution was prepared with 4 ml ECL 
solution A, 1.2 µl H2O2 and 400 µl ECL solution B and carefully poured on the surface of 
the membrane. The production of chemiluminescent oxidized luminol catalysed by HRP was 
detected using the ChemoCam Imager, Intas.   
 Optical methods  
4.2.4.1 Confocal microscopy 
The intracellular localization of citrine-tagged variants of proteins was observed via confocal 
laser scanning microscopy (Leice) as described in (Lösing et al., 2012). 1 – 2 million cells 
were harvested by centrifugation at 400 g for 3 min and washed twice with 1 ml Krebs-
Ringer solution, containing 1mM CaCl2 and finally resuspended in 800 µl Krebs-Ringer 
solution. The sample was distributed amongst two wells of a microscope chamber with 400 
µl added to each. Prior to the imaging, the cells were rested in the wells for about 30 min to 
allow them to settle to the bottom of the well.  
 
4.2.4.2 Ca2+ mobilization  
Ca2+ flux and changes in the intracellular Ca2+ concentrations on BCR ligation was 
monitored with the help of the flowcytometer as described in Stork et. al. The Ca2+ sensitive 
dye INDO-1, that was used, has emission maximum at 475 nm in its free form and at 400 
nm in its Ca2+ bound form. 1.5 – 2x106 cells were pelleted by centrifugation at 300 g for 4 
min and resuspended in 700 µl RPMI-1640 medium with 5% FCS. Next, 2.1 µl pluronic 
acid (5%) and 0.7 µl INDO-1 AM was added to each sample, which was then incubated at 
30 °C for 25 min. After this, 800 µl RPMI-1640 containing 10 % FCS was added and the 
samples were further incubated at 37 °C for 10 min. The cells were then pelleted and washed 
twice with Krebs-Ringer solution containing 1mM CaCl2 and finally resuspended in 600 µl  
 





Krebs-Ringer solution. The cells were then rested for at least 25 °C to ensure a stable baseline 
for fluorescence signals. The fluorescence intensity for INDO-1 violet and blue was recorded 
for 30 sec. The ratio of these values gave an indication of the levels of intracellular Ca2+ 
concentrations. After the baseline acquisition, the cells were stimulated with the stimulating 
antibody and the fluorescence signal was recorded.   
 
4.2.4.3 Analysis of cell surface-BCR expression level 
To quantify the expression level of membrane bound IgM (for DG75 cells) and IgG (for 
IIA1.6 cells) BCRs, 1-1.5 million cells were harvested by centrifugation at 300 g, 4min and 
washed with 1X cold PBS. The cell pellet was then resuspended in 100 µl of 1X PBS and 1 
µl of either anti-human IgM-APC or anti-mouse IgG-CY5 was added. The cells were then  
incubated on ice, in the dark for about 20 min. This was followed by centrifugation of the 
samples 300 g, 4 °C, 4 min and the washing away of the unbound antibodies using cold PBS 
and centrifuging again 300 g, 4 °C, 4 min. Finally, the cells were resuspended in 300 µl cold 
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°C degree Celsius g times gravity  
µ micro GEF Guanine nucleotide exchange 
factor  
A ampere GFP Green fluorescent protein  
aa amino acid GC Germinal center  
α anti  HRP  Horse radish peroxidase  
A Alanine or Adenine Ig Immunoglobulin  
Ag antigen Igα Immunoglobulin α  
ADCC Antibody-dependent cell-
mediated cytotoxicity 
Ig β Immunoglobulin β  
CD Cluster of differentiation  Ig Immunoglobulin  
CRAC Ca2+ release-activated 
channel  
IP3  Inositol-1,4,5,-triphosphate  
CIN85 Cbl-interacting protein of 85 
kDa 
IP3R  Inositol-1,4,5,-triphosphate 
receptor  
CD2AP CD2 Associated Protein ITAM Immunoreceptor tyrosine-based 
activation motif  
DAG Diacylglycerol  ITT Immunoglobulin tail tyrosine  
ddH2O Double distilled water  kDa  Kilo Dalton  
Δ deletion/truncation MAPK  Mitogen activated protein kinase  
dKO Double knock out NFAT Nuclear factor or activated T 
cells  
ERK  Extracellular signal regulated 
kinase  
NF-κB  Nuclear factor kappa of 
activated B cells  
ER  Endoplasmic reticulum  NP-40  Nonidet P-40 or 
octylphenoxypolyethoxyethanol  
F(ab’)2  Dimer of antigen binding 
fragment  
PBS  Phosphate buffered saline  
FACS  Fluorescence activated cell 
sorting  
PI3K  Phosphoinositide 3-kinase  
FcγR  Fc epsilon receptor     




    
    
PIP3  Phosphatidyl-inositol-3,4,5-
trisphosphate  
Sos  Son of sevenless  
SH3  Src homology 3 domain  Syk  Spleen tyrosine kinase  
sKO Single knock out V(D)J Variable (V), Diversity (D), 
Joining (J) gene segments of the 
Ig heavy chain or Ig light chain  
SLP65  Src homology 2 domain 
containing protein of 65 kDa  




G deoxyguanosine monophosphate 
A deoxyadenosine monophosphate 
T deoxythymidine monophosphate 
C deoxycytidine monophosphate 
 
Single-letter Amino Acid Code  
Amino acid Three letter code One letter code 
alanine ala A 
arginine arg R 
asparagine asn N 
aspartic acid asp D 
asparagine or aspartic acid asx B 
cysteine cys C 
glutamic acid glu E 
glutamine gln Q 
glutamine or glutamic acid glx Z 
glycine gly G 
histidine his H 






isoleucine ile I 
leucine leu L 
lysine lys K 
methionine met M 
phenylalanine phe F 
proline pro P 
serine ser S 
threonine thr T 
tryptophan trp W 
tyrosine tyr Y 
valine val V 
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